CA2135890C - Retroviral protease inhibitor (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4- thiazolyl)methyl)amino)carbonyl)valinyl)amino)- 2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1, 6-diphenyl-3-hydroxyhexane - Google Patents

Abstract

A retroviral protease inhibiting compound of formula (A) <IMG> wherein R1 is 2-isopropylthiazol-4-yl; n is 1; R2 is hydrogen; R3 is isopropyl; R4 and R4a are phenyl; R6 is hydrogen; R7 is thiazol-5-yl; X is hydrogen and Y is -OH; and Z is -N(CH3)-; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Description

21 3589~

~ /

RETROVIRAL PROTEASE INHIBITING COMPOUND

Technical Field The present invention relates to novel compounds and a composition and method for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease, a composition and method for treating a retroviral infection and in particular an HIV infection, processes for making such compounds and synthetic intermediates employed in these processes.

Background of the Invention Retroviruses are those viruses which utilize a ribonucleic acid (RNA) intermediate and a RNA-dependent deoxyribonucleic acid (DNA) polymerase, reverse transcriptase, during their life cycle. Retroviruses include, but are not limited to, the RNA viruses of the Retroviridae family, and also the DNA virusesof the Hepadnavirus and Caulimovirus families. Retroviruses cause a variety of disease states in man, animals and plants. Some of the more important retroviruses from a pathological standpoint include human immunodeficiency viruses (HIV-1 and HIV-2), which cause acquired immune deficiency syndrome (AIDS) in man, hepatitis B virus, which causes hepaIitis and hepatic carcinomas in rr!an, human T-cell Iymphotrophic viruses 1, Il, IV and V, which cause human acute cell leukemia, and bovine and feline leukemia viruses which cause leukemia in domestic animals.
Proteases are enzymes which cleave proteins at specific peptide bonds.
Many biological functions are controlled or mediated by proteases and their complementary protease inhibitors. For example, the protease renin cleaves the peptide angiotensinogen to produce the peptide angiotensin 1. Angiotensin t ~ ~

I is further cleaved by the protease angiotensin converting enzyme (ACE) to form the hypotensive peptide angiotensin ll. Inhibitors of renin and ACE are known to reduce high blood pressure in vivo. An inhibitor of a retroviral protease will provide a therapeutic agent for diseases caused by the retrovirus.The genomes of retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the ~olandg~g,geneproducts. SeeWellink,Arch.Virol.981 (1988). Retroviral proteases most commonly process the gag precursor into core proteins, and also process the ~Q! precursor into reverse transciptase and retroviral protease.
In addition, retroviral proteases are sequence specific. See Pearl, Nature 328 4~2 (1987) The correct processing of the precursor polyproteins by the retroviral protease is necessary for the assembly of infectious virions. It has been shown that in vitro mutagenesis that produces protease-defective virus leads to the production of immature core forms which lack infectivity. See Crawford, J. Virol.
53 899 (1985); Katoh, et al., Virology 145 280 (1985). Therefore, retroviral protease inhibition provides an attractive target for antiviral therapy. See Mitsuya, Nature 325 775 (1987).
Current treatments for viral diseases usually involve administration of compounds that inhibit viral DNA synthesis. Current treatments for AIDS involve administration of compounds such as 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxycytidine (DDC) and 2',3'-dideoxyinosine (DDI) and compounds which treat the opportunistic infections caused by the immunosuppression resulting from HIV infection. None of the current AIDS treatments have proven to be totally effective in treating and/or reversing the disease. In addition, many of the compounds currently used to treat AIDS cause adverse side effects including low platelet count, renal toxicity and bone marrow cytopenia.

~s~

Disclosure of the Invention In accordance with the present invention, there is a retroviral protease inhibiting compound of the formula A:

H R J

wherein R1 is 2-isopropylthiazol-4-yl;

nis 1;

R2 is hydrogen;

R3 is isopropyl;

R4 and R4a are phenyl;

R6 is hydrogen;

R7 is thiazol-5-yl;

X is hydrogen and Y is -OH; and Z is -N(CH3)-; or a pharmaceutically acceptable salt, ester or prodrug thereof.

The most preferred compound of the formula A is the compound wherein the configuration of the carbon atom bearing -CH2R4 is "S" and the configuration of the carbon bearing Y is "S" and the configuration of the carbon atom bearing -CH2(R4a) is "S".
In particular the invention provides the compound of formula:

s~CH3 ~ o S>

CH3 CH3 ~ N

~

which is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-iso-propyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically accept-able salt or prodrug thereof.
The compounds of the invention comprise asymmetrically substituted centers (i.e., asymmetrically substituted carbon atoms). The present invention is intended to include all stereoisomeric forms of the compounds, including racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds of the invention. The terms "S" and "R" configuration are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-30.

21 3~890 -4a-The term "Val" as used herein refers to valine. Unless otherwise noted, when "Val" is used herein it refers to the L-isomer. In general, the amino acid abbreviations used herein follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature for amino acids and peptides (Eur. J. Biochem. 1984, 158, 9-31).
The term "N-protecting group" or "N-protected" as used herein refers to those groups intended to protect the N-terminus of an amino acid or peptide or to protect an amino group against undesirable reactions during synthetic procedures.
Commonly used N-protecting groups are disclosed in Greene, "Protective Groups In Organic Synthesis", (John Wiley & Sons, New York (1981). N protecting groups comprise acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl,phthalyl, o-nitrophenoxyacetyl, ~-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitro-benzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like;
carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxy, p-methoxybenzyloxycarbonyl, p-nitro-benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromo-benzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyl-oxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxy-carbonyl, l-(p-biphenylyl)-l-methylethoxycarbonyl, a,~
dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryl-oxycarbonyl, E

t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl and the like; alkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the like. Preferred N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
The term "O-protecting group" as used herein refers to a substituent which protects hydroxyl groups against undesirable reactions during synthetic procedures such as those O-protecting groups disclosed in Greene, "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)). O-protecting groups comprise substituted methyl ethers, for example, methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, t-butyl, benzyl and triphenylmethyl; tetrahydropyranyl ethers; substituted ethyl ethers, for example, 2,2,2-trichloroethyl; silyl ethers, for example, trimethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl; and esters prepared by reacting the hydroxyl group with a carboxylic acid, for example, acetate, propionate, benzoate and the like.

The term "activated ester derivative" as used herein refer to acid halides such as acid chlorides, and activated esters including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides such as isobutyloxycarbonylchloride and the like, N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters, N-hydroxy-5-norbornene-2,3-dicarboxamide derived esters, 2,4,5-trichlorophenol derived esters and the like.
The term "loweralkyl" as used herein refers to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.

The term "alkylamino" as used herein refers to a loweralkyl radical appended to an -NH radical.
The term "cycloalkyl" as used herein refers to an aliphatic ring having 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl and the like. A preferred cycloalkyl group is cyclopropyl The term "cycloalkylalkyl" as used herein refers to a cycloalkyl group appended to a loweralkyl radical, including but not limited to cyclohexylmethyl.The terms "alkoxy" and "thioalkoxy" as used herein refer to R150- and R1 5S-, respectively, wherein R15 is a loweralkyl group or benzyl.
The term "alkoxyalkyl" as used herein refers to an alkoxy group appended to a loweralkyl radical.
The term "thioalkoxyalkyl" as used herein refers to a thioalkoxy group appended to a loweralkyl radical.
The term "dialkylamino" as used herein refers to -NR16R17 wherein R16 and R17 are independently selected from loweralkyl groups.
The term "dialkylaminoalkyl" as used herein refers to -NR1 8R1 9 which is appended to a loweralkyl radical wherein R18 and R19 are independently selected from loweralkyl.
The term "halo" or "halogen" as used herein refers to -Cl, -Br, -I or -F.
The term "heterocyclic" as used herein refers to a heterocyclic group selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, loweralkyl, hydroxy, alkoxy and thioalkoxy.

A preferred compound of the invention is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt, ester or prodrug thereof.

. ~

Compounds useful as intermediates for the preparation of the compound of formula A include the compound of the formula A3:
.

R*
o,B~ NH
H2N ~ R4 4a A3 wherein R4 and R4a are phenyl; and R* is phenyl, halo-substituted phenyl, dihalo-substituted phenyl, alkoxy-substituted phenyl, loweralkyl-substituted phenyl, bis-trifluormethyl-substituted phenyl or naphthyl or loweralkyl; or an acid addition salt thereof.

Preferred intermediates are compounds of the formula A4:

R*
I

O~ ~ NH
H2N 1~,~ R4 R4a A4 wherein R4 and R4a are phenyl; and R* is phenyl, halo-substituted phenyl, dihalo-substituted phenyl, alkoxy-substituted phenyl, loweralkyl-substituted phenyl, bis-trifluormethyl-substituted phenyl or naphthyl or loweralkyl; or an acid addition salt thereof.
Most prefe~red compounds of the formula A4 are those wherein R* is phenyl.

~r ~J

1 The compound of the invention can be prepared as shown in Schemes 1 - 8. As outlined in Scheme 1, coupling of protected a-aminoaldehyde la and Ib (R30 is loweralkyl or benzyl) with VCI3(tetrahydrofuran)3 and Zn produces a mixture of diols, out of which compounds ll and lll can be isolated. Hydrolysis of ll and lll with barium hydroxide leads, respectively, to diaminodiols IV and V.
Alternately, treatment of ll with a-acetoxyisobutyryl bromide in acetonitrile leads to compound Vl, which upon hydrolysis with barium hydroxide, produces diaminodiol Vll.

S~eme1 H R4a R4a R~O N_ CHO H OH ~ O OH
- R~O ~ N~'~_~-N ~ OR~ ~ :

4 O ' OH H ' OH

R~O N~CHOH OH . O OH ~ 4a E R~O ~ N ~ N ~ OR~ ~ ~ H2N ~ NH2 R4a O ' OH H ' OH

H OAc ~ OH .

R4~ ~oH ~ HzN ~ NH2 Vl Vll ~L ~

2 t 35890 i As outlined in Scheme 2, treatment of compound 11 with a-acetoxy-isobutyryl bromide in hexane/dichloromethane produces bromoacetate Vlll.
Hydrolysis of Vlll with concommitant cyclization produces epoxide IX, which is reduced with sodium borohydride and trifluoroacetic acid to produce compound X. Barium hydroxide hydrolysis of X leads to diamine Xl.

Scheme 2 R4a R4a H OH ~ O H OAc ~ O
R30O~N~`N OR30 ; R300~N~N~OR30 O~ OH H R4 Br H
Vlll R4a ~ R4a H~`N OR30 f H~;N OR30 X lX

OH ~R4a 'C
.. ~

1 As outlined in Scheme 3, compound XX (R3 is isopropyl) is converted to isocyanate XXI by treatment with phosgene. Alternatively, treatment of XX with 4-nitrophenyl chloroformate produces carbamate XXII. Condensation of either XXI or XXII with compound XXIII wherein Z is N(CH3), with catalytic 4-dimethylaminopyridine as needed, provides compound XXIV. Lithium hydroxide hydrolysis of XXIV produces compound XXV.

Sd~eme 3 O=C=N CO2CH3 R3 ~ X)U Ih~ 'h2` R3 HCI H2N C02CH3 R1y~ ZH R1~ Z~ Nl CO2CH3 XX \~ X~UII~ H

~ O NCO2CHXXIV
H h2\ 0 R3 Rl~Z~N~ CO2H
XXV

.~

1 As outlined in Scheme 4, compound XXVIII (X is H, Y is -OH) is acylated with an activated derivative of XXVI having the formula (R6)(R7)CHOC(O)OL
wherein L is an activating group for the acylation reaction such as p-nitrophenyl, phenyl, N-succinimidyl, N-phthalimidyl, N-benzotriazolyl, N-5-norbornene-2,3-carboxamidyl or 2,4,5-trichlorophenyl and the like (for example, XXVII, which isprepared by reacting XXVI with 4-nitrophenyl chloroformate) to provide a mixture of compounds XXlXa and XXlXb or an acid addition salt thereof.
Coupling of XXlXa to compound XXX by treatment with a carbodiimide (or by reaction with an activated ester of XXX) produces compound XXXla.
Scheme 4 R6 R4a H 1XVIR7 H2N~N, 01 R7 ~ R4 xYxlxaH

X R4a~0 ~01 R Y R40 R
R4 NH2 XXVII ~aXXlXb zJlN~N~

XXXla As outlined in Scheme 5A, treatment of diamine Xl with a boronic acid (preferably, phenylboronic acid) or a boroxine produces compound XXXII, which is selectively acylated with an activated derivative of XXVI having the formula (R6)(R7)CHOC(O)OL wherein L is an activating group for the acylation reaction such as p-nitrophenyl, phenyl, N-succinimidyl, N-phthalimidyl, N-benzotriazolyl, N-5-norbornene-2,3-carboxamidyl or 2,4,5-trichlorophenyl and the like (for example, XXVII) to provide compound XXXllla or an acid addition salt thereof. Carbodiimide-mediated coupling of XXXllla to compound XXX (or reaction of XXXllla with an activated ester of XXX) leads to compound XXXlVa. In a preferred embodiment of the process shown in Scheme 5A, R~ is phenyl.
Scheme 5A

OH ~ R4a R~B(OH)2 O, B~ N~ H
H2N~ NH2 2 -~ R4a R; r R, R ~ XXXH

/R\ R3 H ~R4 ~R4 R1W~~ N~;~ N~ O1 R7 ~ H2N~ N~ 1 R7 n H O ~ OH H ~R O R3 R~ OH H
XXXlVa R1~ n Z~N~CO2H 4a XXXIIIa XXX

!. ~
~,~.

1 Scheme 5B outlines an alternative preparation of XXXllla. Reaction of compound Xl with (i) two equivalents of B(OR**)3 wherein R** is loweralkyl (preferably, isopropyl) or (ii) two equivalents of B(R***)3 wherein R*** is halo (preferably, fluoro) and four equivalents of an amine such as triethylamine in an inert solvent such as tetrahydrofuran, followed by reaction with an activated derivative of XXVI having the formula (R6)(R7)CHOC(O)OL wherein L is an activating group for the acylation reaction such as p-nitrophenyl, phenyl, N-succinimidyl, N-phthalimidyl, N-benzotriazolyl, N-5-norbornene-2,3-carboxamidyl or 2,4,5-trichlorophenyl and the like (for example, XXVII), gives compound XXXllla or an acid addition salt thereof. In the preferred embodiment of the process shown in Scheme 5B, R** is isopropyl or R*~* is fluoro.

Scheme 5B

1) B(OR*~h or B(R~*~)3 Xl ~ XXXllla 2) XXVII

Scheme 5C outlines an alternative preparation of XXXlVa. Reaction of compound Xl with two molar equivalents of Ti(OR****)4 wherein R**** is loweralkyl (preferably, isopropyl), followed by reaction with compound XXX (or an activated ester derivative thereof), provides compound XLIII or an acid addition salt thereof. Reaction of compound XLIII with an activated derivative of XXVI having the formula (R6)(R7)CHOC(O)OL wherein L is an activating group for the acylation reaction such as p-nitrophenyl, phenyl, N-succinimidyl, N-phthalimidyl, N-benzotriazolyl, N-5-norbornene-2,3-carboxamidyl or 2,4,5-trichlorophenyl and the like (for example, XXVII) gives compound XXXlVa. In the preferred embodiment of the process shown in Scheme 5C, R**** is isopropyl.

Scheme 5C

1) Ti(OR~A~)4 R2\ O R3 ,H ,R4 H N~ 2) XXX R1J~Z~NJ~NH2 v I R4a ^' XLIII

XXVII
-Rl~ Z~N~ N ~`N ~ 01 R
H OR~ OH H

XXXlVa Scheme 6 shows an alternative preparation of diaminomono-ol Xl.
Reaction of ketonitrile XXXV with Grignard reagent R4aCH2MgX provides ketoenamine XXXVI. Reaction of the ketoenamine with NaBH4/CH3SO3H, followed by reaction of the resulting intermediate (without isolation) with NaBH4/CF3CO2H, provides XXXVII. Hydrogenation of the benzyl groups gives Xl. Alternatively, protection of the free amino group of XXXVII as the t-butyloxycarbonylamino group, followed by hydrogenation of the benzyl groups, gives XXXVIII.

C~

1 Scheme 6 Ph' Ph Ph Ph R - 1. R - ~ ~N CN

Ph = phenyl XXXV

Ph Ph Ph Ph ~NJ - ~NJ
Xxxv ~ R4 ~f R4a ~ R4 R4a XXXV I
XXXVII

XXXVII ~ Xl Ph Ph - R4a ~ ~` ~ R4a O H NHBoc O H NHBoc XXXVI l I

V~'`

! Scheme 7 shows an alternative preparation of XXXVIII. N-protection of XXXVI gives XXXIX. Reaction of XXXIX with borane-tetrahydrofuran complex, followed by reaction of the resulting product with LiAlH4 or KBH4, provides the N,N-dibenzyl precursor to XXXVIII.
Scheme 7 Ph Ph Ph Ph ~N ~N
R4 ~ R4a ~ - R4a O NHBoc XXXVI XXXIX
Ph = phenyl Ph' Ph XXXIX ~ N NH2 R4 R4a R4 ~R4a O H NHBoc O H NHBoc XXXVIII

1 Scheme 8 shows how the selectively protected diamine XXXIX can be used to prepare the compound of the invention XL.

Scheme 8 R4a OH NHBoc / XXXVIII
XXVII /

BocNH~ R6 OH H
R4a N-deprotection H
XXX

Rl~ Z ~ ~ O R6 n H O j OH H
R4a XL

The following examples will serve to further illustrate the preparation of the novel compound of the invention.
Example 1 A. N-(((Benzyl)oxy)carbonyl)-L-phenylalaninal.
A solution of 24.5 ml of anhydrous dimethyl sulfoxide in 870 ml of anhydrous dichloromethane was cooled under N2 atmosphere to -60C and treated over a period of 15 min with 131 ml of a 2 M solution of oxalyl chloride in dichloromethane in order that the internal temperature remained below -50C.
After addition, the solution was stirred at -60C for 15 min and treated over a period of 20 min with a solution of 50 g (0.175 mol) of N-(((benzyl)oxy)-carbonyl)-L-phenylalaninol in 200 ml of dichloromethane. The resulting solution was stirred at -60C for 1 h, then treated over a period of 15 min with 97 ml of triethylamine in order that the internal temperature remained below -50C.After addition the solution was stirred at -60C for 15 min, then, with the cooling bath in place, was treated rapidly (over a period of 1 min) with a solution of 163 g of citric acid in 550 ml of water. The resulting slurry was stirred vigorously for 10 min, allowed to warm, diluted to 1 liter with water, and separated. The organic layer was washed with 700 ml of water followed by a mixture of 550 ml of water and 150 ml of saturated aqueous NaHCO3, dried over MgSO4, and concentrated in vacuo at 20C to give the crude desired compound as a light yellow solid.

B. (2S.3R.4R.5S)-2.5-Bis-(N-(((benzyl)oxy)carbonyl)amino)-3.4-dihydroxy-1.6-diphenylhexane and (2S.3S.4S.5S)-2.5-Bis-(N-(((benzyl)oxy)carbonyl)amino)-3.4-dihydroxy-1.6-diphenylhexane.
A suspension of 78.5 g of VCI3-(tetrahydrofuran)3 and 16 g of zinc dust in 400 ml of dry dichloromethane was stirred under N2 atmosphere for 1 h at 25C.
A solution of 0.175 mol of N-(((benzyl)oxy)carbonyl)-L-phenylalaninal in 200 ml of dichloromethane was then added in one portion, and the resulting mixture was stirred at ambient temperature under N2 atmosphere for 16 h. The resulting mixture was added to 500 ml of 1 M aqueous HCI, diluted with 500 ml of hot chloroform, and shaked vigorously for 2 min. The layers were separated, and the organic layer was washed with 1 M aqueous HCI and separated. Filtration I of the organic phase provided the crude desired product as a solid residue. The residue was slurried in 1.25 liters of acetone, treated with 5 ml of concentrated H2SO4, and stirred for 16 h at ambient temperature. The resulting mixture was filtered,-and the residue (residue A) was washed wit~ 50 ml of acetone. The combined filtrate was concentrated to a volume of 250 ml, diluted with 1000 ml of dichloromethane, washed three times with water and once with saturated brine, dried over MgSO4, and concentrated to give a viscous oil. The oil was taken up in 1000 ml of 1 M HCI in methanol (prepared from 71 ml of acetyl chloride and 1000 ml of methanol) and stirred at ambient temperature for 2 h. The resulting precipitate was filtered, washed with methanol, and air-driedon the filter to provide 26.7 g of the desired compound as a white solid. The filtrate was concentrated and filtered to give a second crop (8.3 g) of (2S,3R,4R,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane. 1 H NMR (d6-DMSO) ~ 2.59 (dd, J = 13, 5 Hz, 2 H), 2.74 (dd, J
= 13,9 Hz,2 H),3.26 (br, 2 H),4.19 (m, 2 H), 4.54 (m, 2 H),4.92 (m,4 H), 6.82 (d, J = 9 Hz,2 H),7.0-7.35 (m,20 H). Mass spectrum: (M + H)+ = 569.
Residue A (above, 2.65 g) was suspended in 75 ml of tetrahydrofuran (THF) and 75 ml of 1 M aqueous HCI and heated at reflux for 24 h. After concentration of the resulting solution in vacuo, the residue was taken up in 10% methanol in chloroform, washed two times with water, dried over Na2SO4, and concentrated in vacuo to provide (2S,3S,4S,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane as a white solid. 1 H NMR (d6-DMSO) ~ 2.64 (m, 2 H), 3.04 (m, 2 H), 3.49 (m, 2 H), 3.78 (m,2 H), 4.70 (d, J = 7 Hz, 2 H), 4.93 (M', 4 H),7.1-7.4 (m, 20 H). Mass spectrum:
(M + H)+= 569.

C. (2S~3R.4S.5S)-3-Acetoxy-2.5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3-bromo-1.6-diphenylhexane.
A suspension of 25 g (44 mmol) of (2S,3R,4R,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane in 500 ml of 2:1 dichloromethane/hexane was treated with 23 g of a-acetoxyisobutyryl bromide. The resulting mixture was stirred at ambient temperature until the reaction clarified, washed with two 200 ml portions of saturated aqueous ~r ? ~

-20- 1 2 1 3~890 NaHCO3, dried over MgSO4, and concentrated in vacuo to give 30.8 g of the crude desired compound. A portion was purified by silica gel chromatography using 9:1 dichloromethane:ethyl acetate to provide the pure desired compound as a white solid. 1 H NMR (CDCI3) ~ 2.21 (s, 3 H), 2,62 (dd, J = 13, 1 1 Hz, 1 H), 2.75 (d, J = 7 Hz, 2 H), 2.95 (br d, J = 15 Hz, 1 H), 4.03 (brt, J = 10 Hz, 1 h), 4.40 (br d, J = 10 Hz, 1 H), 4.6-5.0 (m, 6 H), 5.12 (br d, J = 13 Hz, 1 H), 5.33 (br d, J =
11 Hz, 1 H), 7.0-7.4 (m, 10 H). Mass spectrum: (M + NH4)+ = 690, 692.

D. (2S.3R.4R.5S)-2.5-Bis-(N-(((benzyl)oxy)carbonyl)amino)-3.4-epoxy-1.6-diphenylhexane.
A solution of 35.56 g (52.8 mmol) of (2S,3R,4S,5S)-3-acetoxy-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3-bromo-1,6-diphenylhexane in 375 ml of dioxane was treated with 255 ml of 1 N aqueous sodium hydroxide and stirred at ambient temperature for 16 h, during which the desired compound precipitated.
The resulting mixture was filtered, and the residue was washed with water and dried to provide 22.23 9 (76%) of the desired compound as a white solid. 1 H
NMR (CDCI3) â 2.7-2.9 (m, 6 H), 3.9-4.0 (m, 2 H), 4.6-4.7 (m, 2 H), 5.03 (m, 4 H), 7.1-7.4 (m, 10 H).

E. (2S.3S.5S)-2.5-Bis-(N-(((benzyl)oxy)carbonyl)amino)-1.6-diphenyl-3- hydroxyhexane.
A mixture of 39.2 9 (71.2 mmol) of (2S,3R,4R,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-epoxy-1,6-diphenylhexane in 600 ml of THF
was treated under N2 atmosphere with 13 g (0.36 mol) of sodium borohydride.
The resulting mixture was treated dropwise with 27.7 ml (0.36 mol) of trifluoroacetic acid. After being stirred for 3.5 h at ambient temperature, the resulting mixture was quenched with 1 N aqueous HCI, diluted with water, and stirred for 16 h. The resulting mixture was filtered. washed with water, and dried to provide 22.85 9 (58%) of the desired compound as a white solid.

F. (2S.3S.5S)-2.5-Diamino-1.6-diphenyl-3-hydroxyhexane.
A suspension of 32 9 of the crude resultant compound of Example 1 E
and 55.5 9 (176 mmol) of barium hydroxide octahydrate in 400 ml of 1,4-i ~

2 1 3~890 1 dioxane and 400 ml of water was heated at reflux for 4 h. The resulting mixture was filtered, and the residue was rinsed with dioxane. The combined filtrates were concentrated to a volume of approximately 200 ml and extracted with four 400 ml portions of chloroform. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography using first 2% isopropylamine in chloroform and then 2%
isopropylamine/2% methanol in chloroform to provide 10.1 9 (81%) of the pure desired compound as a white solid. 1H NMR (CDCI3) ~ 1.54 (dt, J = 14,10 Hz,1 H),1.67 (dt, J = 14,3 Hz,1 H),2.50 (dd, J = 13, 8 Hz,1 H),2.58 (dd, J = 13, 8 Hz, 1 H),2.8(m,2H),2.91 (dd,J=13,5Hz,1 H),3.10(m,1 H),3.72(ddd,J=11,3, 2 Hz,1 H), 7.1-7.4 (m,10 H). Mass spectrum: (M + H)+= 285.

G. (4S.6S.1'S)-6-(1-Amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane.
A solution of 131 9 (460 mmol) of (2S,3S,5S)-2,5-diamino-1,6-diphenyl-3-hydroxyhexane in 1.2 L of toluene was treated under N2 atmosphere with 56.16 9 (460 mmol) of phenylboric acid. The resulting solution was heated at reflux (bath temperature 135C) and water azeotropically removed with the aid of a Dean Stark trap until the distillate was clear and the theoretical amount of water (15.6 ml) was collected (ca 1.5 h). After being allowed to cool, the solution was concentrated in vacuo to provide 176 9 of the crude desired compound as a resin. H1 NMR (CDCI3) ~ 7.59 (m, 2H), 7.47-7.07 (m,13H, 3.92 (m, 1 H), 3.78 (s br, 1 H), 3.52 (m, 1 H), 3.50 (m, 2H), 2.87 (dd, 1 H, J = 13.5, 5.7 Hz), 2.72 (m, 1H), 2.58 (dd, 1H, J = 13.5, 8.7 Hz), 1.92 (m, 1H), 1.68 (m, 1H), 1.60-1.30 (s-very broad, 2H). CIMS m/z 371 (M + H) H. Thioformamide.
To a cooled (0C) 2 L three neck round bottom flask equipped with an overhead stirrer charged with a solution of formamide (30.5 mL, 0.76 mol) in 1 Lof diethyl ether was added 89 9 (0.19 mol) of phosphorous pentasulfide in small portions. The reaction mixture was allowed to warm to ambient temperature, 2~ 35890 1 stirred for 2 h, filtered, and concentrated in vacuo to afford thioformamide as a yellow offensive smelling oil which was used without purification.

I. Ethyl 2-Chloro-2-formylacetate.
To a three neck 2 L round bottom flask charged with potassium t-butoxide (0.5 mol, 500 mL of a 1 M solution in THF) and 500 mL of dry THF cooled to 0C
was added dropwise from an addition funnel a solution of ethyl chloroacetate (0.5 mol,53.5 mL) and ethyl formate ( 0.5 mol, 40.4 mL), in 200 mL of THF over 3 hours. After completion of addition, the reaction mixture was stirred for 1 hour and allowed to stand overnight. The resulting solid was diluted with diethyl ether and cooled in an ice bath. Then, the pH was lowered to approximately 3 using 6N HCI. The organic phase was separated, and the aqueous layer was washed 3 times with diethyl ether. The combined ethereal portions were dried over NaSO4, and concentrated in vacuo. The crude desired compound was stored at -30C and used without further purification.

J. Ethyl Thiazole-5-carboxylate.
To a round bottom flask was added 250 mL of dry acetone, 7.5 9 (0.123 mol) of thioformamide, and 18.54 g (0.123 mol) of ethyl 2-chloro-2-formylacetate. The reaction was heated at reflux for 2 hours. The solvent was removed in vacuo, and the residue was purified by chromatography (SiO2, 6 cm o.d. column,100% CHCI3, Rf = 0.25) to provide 11.6 g (60%) of the desired compound as a light yellow oil. NMR (CDCI3) ~ 1.39 (t, J = 7 Hz, 3 H), 4.38 (q, J
=7 Hz, 2 H), 8.50 (s,1 H), 8.95 (s,1 H).

K. 5-(Hydroxymethyl)thiazole.
To a precooled (ice bath) three neck 500 mL flask containing lithium aluminum hydride (76 mmol) in 250 mL of THF was added ethyl thiazole-5-carboxylate (11.82 9, 75.68 mmol) in 100 mL of THF dropwise over 1.5 hours to avoid excess foaming. The reaction was stirred for an additional hour, and treated cautiously with 2.9 mL of water, 2.9 mL of 15% NaOH, and 8.7 mL of water. The solid salts were filtered, and the filtrate set aside. The crude salts ~,~ ., ~1 35890 I were heated at reflux in 100 mL of ethyl acetate for 30 min. The resulting mixture was filtered, and the two filtrates were combined, dried over Na2SO4, and concentrated in vacuo. The product was purified by silica gel chromatography eluting sequentially with 0% - 2% -,4% methanol in chloroform, to provide the desired compound, Rf = 0.3 (4% methanol in chloroform), which solidified upon standing in 75% yield. NMR (CDCI3) ~ 4.92 (s, 2 H), 7.78 (s, 1 H), 8.77 (s, 1 H). Mass spectrum: (M + H)+ = 116.

L. ((5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate.
A solution of 3.11 g (27 mmol) of 5-(hydroxymethyl)thiazole and excess N-methyl morpholine in 100 ml of methylene chloride was cooled to 0C and treated with 8.2 g (41 mmol) of 4-nitrophenyl chloroformate. After being stirredfor 1 h, the reaction mixture was diluted with CHCI3, washed successively with 1 N HCI, saturated aqueous NaHCO3, and saturated brine, dried over NaSO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (SiO2, 1-2% MeOH/CHCI3, Rf=0.5 in 4% MeOH/CHCI3) to yield 5.9 g (78%) of the desired compound as a yellow solid. NMR (CDCI3) ~

5.53 (s, 2 H), 7.39 (dt, J = 9, 3 Hz, 2 H), 8.01 (s, 1 H), 8.29 (dt, J = 9, 3 Hz, 2 H), 8.90 (s, 1 H). Mass spectrum: (M + H)+= 281.

M. (2S.3S.5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane and (2S.3S.5S)-2-Amino-5-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1 .6-diphenyl-3-hydroxyhexane.
A solution of 500 mg (1.76 mmol) of (2S,3S,5S)-2,5-diamino-1,6-diphenyl-3-hydroxyhexane and 480 mg (1.71 mmol) of ((5-thiazolyl)methyl)-(4-nitrophenyl)carbonate in 20 ml of THF was stirred at ambient temperature for 4 h. After removal of the solvent in vacuo, the residue was purified by silica gelchromatography using first 2% then S% methanol in chloroform to provide a mixture of the two desired compounds. Silica gel chromatography of the mixture using a gradient of 0 - 1 - 2% methanol in 93:2 isopropylamine:
chloroform provided 110 mg (16%) of (2S,3S,5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane (Rf 0.48, 96:2:2 chloroform:methanol:isopropylamine) and 185 mg (28%) of (2S,3S,5S)-2-~, amino-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,~-diphenyl-3-hydroxyhexane (Rf 0.44, 96:2:2 chloroform:methanol:isopropylamine).

(2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane: NMR (CDCI3) ~ 1.3-1.6 (m, 2 H), 2.40 (dd, J = 14, 8 Hz,1 H), 2.78 (dd, J = 5 Hz,1 H), 2.88 (d, J = 7 Hz, 2 H),3.01 (m,1 H),3.72 (br q,1 H), 3.81 (br d, J = 10 Hz,1 H),5.28 (s,2 H),5.34 (br d, J = 9 Hz,1 H),7.07 (br d, J =
7 Hz, 2 H),7.15 - 7.35 (m,8 H),7.87 (s,1 H),8.80 (s,1 H). Mass spectrum: (M +
H)+ = 426.

(2S,3S,5S)-2-Amino-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane: NMR (CDCI3) ~ 1.55 (dt, J = 14, 8 Hz,1 H),1.74 (m,1 H), 2.44(dd,J=15,1 Hz,1 H),2.75-3.0(m,4H),3.44(m,1 H),4.00(brt,1 H), 5.28 (m,3 H),7.1 - 7.4 (m,10 H),7.86 (s,1 H),8.80 (s,1 H). Mass spectrum: (M
+ H)+ = 426.

N. (2S.3S.5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane.
A solution of 40 mmol of crude (4S,6S,1'S)-6-(1-amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane in 700 ml of anhydrous THF
was cooled to -40C and treated dropwise over a period of 1 h with a solution of7.83 g (27.9 mmol) of ((5-thiazolyl)methyl)-(4-nitrophenyl)carbonate in 300 ml of dry THF. The resulting solution was allowed to warm to 0C for 3 h, then to ambient temperature for 16 h. The solvent was removed in vacuo, and the residue was taken up in 700 ml of ethyl acetate, washed with three 150 ml portions of 1 N aqueous NaOH and one 150 ml portion of brine. The organic phase was dried over Na2SO4 and concentrated in vacuo. Purification of the residue by silica gel chromatography using methanol/chloroform mixtures provided the desired compound mixed with its regioisomer. A second chromatography using 1-3% isopropylamine in chloroform provided 5.21 9 of the desired compound which solidified upon standing.

FC

-25- ~l 35890 O 2-Methylpropane-thioamide.
A suspension of 100 g (1.15 mol) of isobutyramide in 4 L of diethyl ether was stirred vigorously and treated in portions with 51 g (0.115 mol) of P4S10 The resulting n~ixture was stirred at ambient temperature for 2 h, filtered, andconcentrated in vacuo to provide 94.2 9 (80%) of the crude desired compound.
H NMR (DMSO-d6) ~ 1.08 (d, J = 7 Hz, 6 H), 2.78 (heptet, J = 7 Hz,1 H),9.06 (br,1 H),9.30 (br,1 H). Mass spectrum: (M + H)+= 104.

P. 4-(Chloromethyl)-2-isopropylthiazole hydrochloride.
A mixture of 94.0 9 (0.91 mol) of 2-methylpropane-thioamide, 115.7 9 (0.91 mol) of 1,3-dichloroacetone, and 109.7 9 (0.91 mol) of MgSO4 in 1.6 litersof acetone was heated at reflux for 3.5 h. The resulting mixture was allowed to cool, filtered, and the solvent was removed in vacuo to provide the crude desired compound as a yellow oil. 1 H NMR (DMSO-d6) ~ 1.32 (d, J = 7 Hz,6 H), 3.27 (heptet, J = 7 Hz,1 H), 4.78 (s, 2 H), 7.61 (s,1 H). Mass spectrum: (M +
H)+ = 176.

Q. 2-lsopropyl-4-(((N-methyl)amino)methyl)thiazole.
A solution of 40 g of 4-(chloromethyl)-2-isopropylthiazole hydrochloride in 100 ml of water was added dropwise with stirring to 400 ml of 40% aqueous methylamine. The resulting solution was stirred for 1 h, then concentrated in vacuo. The residue was taken up in chloroform, dried over Na2SO4, and concentrated in vacuo. Purification of the residue by silica gel chromatography using 10% methanol in chloroform provided 21.35 g (55%) of the desired compound. 1 H NMR (DMSO-d6) ~ 1.34 (d, J = 7 Hz, 6 H), 2.56 (s, 3 H), 3.30 (heptet, J = 7 Hz,1 H),4.16 (s, 2 H), 7.63 (s,1 H). Mass spectrum: (M + H)+ =
171.

R. N-(((4-Nitrophenyl)oxy)carbonyl)-L-valine Methyl Ester.
A solution of 66.1 g (0.328 mol) of 4-nitrophenyl chloroformate in 1.2 liters of CH2CI2 was cooled to 0C and treated with L-valine methyl ester hydrochloride. The resulting mixture was treated slowly, with stirring, with 68.9 ml (0.626 mol) of 4-methylmorpholine. The resulting solution was allowed to -slowly warm to ambient temperature and was stirred overnight. After washing with 3 portions of 10% aqueous NaHCO3, the solution was dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography by eluting with chloroform to provide the desired compound.
1 H NMR (DMSO-d6) ~ 0.94 (d, J = 7 Hz, 3 H),0.95 (d, J = 7 Hz, 3 H), 2.12 (octet, J=7Hz,1 H),3.69(s,3H),4.01 (dd,J=8,6Hz,1 H),7.41 (dt,J=9,3Hz,2H), 8.27 (dt, J = 9,3 Hz, 2 H), 8.53 (d, J = 8 Hz,1 H). Mass spectrum: (M + NH4)+ =
314.

S. N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine Methyl Ester.
A solution of 15.7 9 (92 mmol) of 2-isopropyl-4-(((N-methyl)amino)-methyl)thiazole in 200 ml of THF was combined with a solution of 20.5 g (69 mmol) of N-(((4-nitrophenyl)oxy)carbonyl)-L-valine methyl ester. The resulting solution was treated with 1.6 9 of 4-dimethylaminopyridine and 12.9 ml (92 mmol) of triethylamine, heated at reflux for 2 h, allowed to cool, and concentrated in vacuo. The residue was taken up in CH2CI2, washed extensively with 5% aqueous K2CO3, dried over Na2SO4, and concentrated in vacuo. The resulting product mixture was purified by silica gel chromatography using chloroform as an eluent to provide 16.3 9 (54%) of the desired compound.
1 H NMR (DMSO-d6) ~ 0.88 (d, J = 7 Hz,3 H),0.92 (d, J = 7 Hz,3 H),1.32 (d, J =
7 Hz, 3 H), 2.05 (octet, J = 7 Hz,1 H), 2.86 (s,3 H), 3.25 (heptet, J = 7 Hz,1 H), 3.61 (s, 3 H), 3.96 (dd, J _8,7 Hz,1 H),4.44 (AA', 2 H),6.58 (d, J = 8 Hz,1 H), 7.24 (s,1 H). Mass spectrum: (M + H)+ = 328.

T. N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine.
A solution of 1.42 g (4.3 mmol) of the resultant compound of Example 1 S
in 17 ml of dioxane was treated with 17.3 ml of 0.50 M aqueous LiOH. The resulting solution was stirred at ambient temperature for 30 min, treated with 8.7 ml of 1 M HCI, and concentrated in vacuo. The residue was taken up in dichloromethane, washed with water, dried over Na2SO4, and concentrated in vacuo to provide 1.1 g (81 %) of the desired compound. Mass spectrum: (M +
H)+ = 314.

2t 35890 U. (2S.3S.5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane.
A solution of 70 mg (0.223 mmol) of N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine, 79 mg (0.186 mmol) of (2S,3S,5S)-5-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, 30 mg (0.223 mmol) of 1-hydroxybenzotriazole hydrate, and 51 mg (0.266 mmol) of N-ethyl-N'-dimethylaminopropyl carbodiimide in 2 ml of THF
was stirred at ambient temperature for 16 h. The resulting solution was concentrated in vacuo, and the residue was purified by silica gel chromatography using 97:3 CH2CI2:CH3OH to provide 100 mg (74%) of the desired compound (Rf 0.4, 95:5 CH2CI2:CH3OH) as a solid.
H NMR (d6-DMSO) ~ 0.73 (d, J = 7 Hz,6 H),1.30 (d, J = 7 Hz,6 H),1.45 (m, 2 H),1.87 (m,1 H), 2.5-2.7 (m,4 H), 2.87 (s, 3 H),3.23 (heptet, J = 7 Hz,1 H), 3.57 (m,1 H),3.81 (m,1 H),3.93(m,1 H),4.15(m,1 H),4.44(AA',2H),4.62(d,J=6 Hz,1 H),5.13 (AA', 2 H),6.01 (d, J = 9 Hz,1 H), 6.89 (d, J = 9 Hz,1 H), 7.1-7.2 (m,11 H), 7.68 (d, J = 9 Hz,1 H), 7.85 (s,1 H),9.05 (s,1 H). Mass spectrum: (M
+ H)+ = 721. Anal. Calcd for C37H48N6OsS2 0.5H2O: C,60.88; H, 6.77; N, 11.51. Found: C, 60.68; H,6.53; N,11.36.

Example 2 (2S. 3S. 5S)-2.5-Diamino-3-hydroxy-1.6-diphenylhexane dihydrochloride Example 2A
(L)-N.N-Dibenzylphenylalanine benzyl ester A solution containing L-pher~ylalanine (11 kg, 66.7 moles), potassium carbonate (29 kg, 210 moles), and water (66 L), and benzyl chloride (27 kg, 213 moles) was heated to 90+15 C for 10-24 hours. The reaction mixture was cooled to room temperature and heptane (29 L) and tap water (27 L) was added. The layers were separated and the organics washed one to two times with 22 L of a methanol/water solution (1/2 v/v). The organics were then stripped to give the desired product as an oil. IR (neat) 3090, 3050, 3030,1730, -28- ~1 35890 I 1495, 1450, 1160 cm~1, 1 H NMR (300 MHz, CDCI3) ~ 7.5-7.0 (m, 20H), 5.3 (d, 1H, J = 13.5 Hz), 5.2 (d, 1H, J = 13.5 Hz), 4.0 (d, 2H, J = 15 Hz), 3.8 (t, 2H, J =
8.4 Hz), 3.6 (d, 2H, J = 15 Hz), 3.2 (dd, 1H, J = 8.4, 14.4 Hz), 13C NMR (300 MHz, CDCI3) ~172.0, 139.2, 138.0, 135.9, 129.4, 128.6, 128.5, 128.4, 128.2, 128.1, 128.1, 126.9, 126.2, 66.0, 62.3, 54.3, 35.6. [a]D -79 (c = 0.9, DMF).

Example 2B
(4S)-4-(N .N-Dibenzylamino)-3-oxo-5-phenyl-pentanonitrile A solution containing the product of Example 2A (i.e., benzyl ester) (approx. 0.45 moles) in 520 mL tetrahydrofuran and 420 mL acetonitrile was cooled to -40C under nitrogen. A second solution containing sodium amide (48.79, 1.25 moles) in 850 mL tetrahydrofuran was cooled to -40C. To the sodium amide solution was slowly added 75 mL acetonitrile and the resulting solution was stirred at -40C for more than 15 minutes. The sodium amide/acetonitrile solution was then slowly added to the benzyl ester solution at -40C. The combined solution was stirred at -40C for one hour and then quenched with 1150 mL of a 25% (w/v) citric acid solution. The resulting slurry was warmed to ambient temperature and the organics separated. The organics were then washed with 350 mL of a 25% (w/v) sodium chloride solution, then diluted with 900 mL heptane. The organics were then washed three times with 900 mL of a 5% (w/v) sodium chloride solution, two times with 900 mL of a 10%
methanolic water solution, one time with 900 mL of a 15% methanolic water solution, and then one time with 900 mL of a 20% methanolic water solution.
The organic solvent was removed in vacuo and the resulting material dissolved into 700 mL of hot ethanol. Upon cooling to room temperature, the desired product precipitated. Filtration gave the desired product in 59% yield from the L-phenylalanine. IR (CHCI3) 3090, 3050, 3030, 2250, 1735, 1600, 1490, 1450, 1370, 1300, 1215 cm~1, 1H NMR (CDCI3) ~7.3 (m, 15H), 3.9 (d, 1H, J = 19.5 Hz), 3.8 (d, 2H, J = 13.5 Hz), 3.6 (d, 2H, J = 13.5 Hz), 3.5 (dd, 1 H, J = 4.0, 10.5 Hz), 3.2 (dd, 1H, J = 10.5,13.5 Hz), 3.0 (dd, 1H, J = 4.0, 13.5 Hz), 3.0 (d, 1H, J _ 19.5 Hz), 13c NMR (300MHz, CDCI3) ~197.0,138.4,138.0,129.5, 129.0, 128.8, 128.6, 127.8, 126.4, 68.6, 54.8, 30.0, 28.4. [Cr]D -95 (c = 0.5, DMF).

~, .

-29- ~ 2135890 ExampAlternate preparation of (4S)-4-(N.N-Dibenzylamino)-3-oxo-5-phenyl-pentanonitrile To a flask was charged sodium amide (5.8g, 134mmol) under nitrogen followed by 100mL of methyl t-butyl ether (MTBE). The stirred solution was cooled to 0C. Acetonitrile (8.6mL, 165mmol) was added over 1 minute. This solution was stirred at 5+5C for 30 minutes. A solution of (L)-N,N-dibenzylphenylalanine benzyl ester (25g, 90% pure, 51.6mmol) in 125mL of MTBE was added over 15 minutes and the resulting heterogeneous mixture was stirred at 5+5C until the reaction was complete (approx. 3 hours). The reaction was quenched with 100mL of 25% w/v aqueous citric acid and warmed to 25C before separating the layers. The organics were then washed with 100 mL of H20. The aqueous layer was separated and the organics filtered and concentrated in vacuo. The residue was crystallized from 50mL of ethanol to afford 1 3.8g of the desired product as a white solid.

Example 2D
(5S)-2-Amino-5-(N .N-dibenzylamino)-4-oxo-1 .6-diphenylhex-2-e~ne To a 5 C solution of the product of Example 2B (20 Kg, 29 moles) in 29 L
tetrahydrofuran was added benzylmagnesium chloride (45 Kg, 2M in THF, 84.5 moles). The solution was warmed to ambient temperature and stirred until analysis showed no starting material. The solution was then recooled to 5 C
and 54 L of a 15% citric acid solution was slowly added to quench excess benzylmagnesium chloride. The organics were separated and washed with 27 L 10% sodium chloride and stripped to a solid. The product was stripped again from 27 L ethanol (200 proof) and then dissolved in 67 L hot ethanol (200 proof). After cooling to room temperature and stirring for 12 hours, the resulting product was filtered and dried in a vacuum oven at 30C to give 24 kg of the desired product. mp 101-102C, IR (CDCI3) 3630, 3500, 3110, 3060, 3030, 2230, 1620, 1595, 1520, 1495, 1450 cm~1, 1 H NMR (300 MHZ, CDCI3) d 9.8 (br s,1H),7.2(m,20H),5.1 (s,1H),4.9(brs,1H),3.8(d,2H,J=14.7Hz),3.6(d, 2H, J = 14.7Hz), 3.5 (m, 3H), 3.2 (dd, 1 H, J = 7.5, 14.4 Hz), 3.0 (dd, 1 H, J = 6.6, 1 4.4 Hz), 1 3C NMR (CDCI3) d 1 98.0,1 62.8,1 40.2,1 40.1 ,1 36.0,1 29.5,1 29.3, , ~

~ 1 3~890 I 128.9, 128.7, 128.1, 1 28.0, 127.3, 126.7, 125.6, 96.9, 66.5, 54.3, 42.3, 32.4.
[a]D -147 (c = 0.5, DMF).
Example 2E
(2S, 3S. 5S)-5-Amino-2-(N.N-dibenzylamino)-3-hydroxy-1.6-diphenyl-hexane (i). A suspension of sodium borohydride (6.6 kg, 175 moles) in tetrahydrofuran (157 L) was cooled to less than -10+5C. Methanesulfonic acid (41.6 kg, 433 moles) was slowly added and the temperature kept below 0C
during the addition. Once the addition was complete, a solution of water (6 L, 333 moles), the product of Example 2D (20 kg, 43 moles) and tetrahydrofuran (61 L) was slowly added while maintaining the temperature below 0 Cduring the addition. The mixture was stirred for not less than 1 9h at 0+5C.
(ii). To a separate flask was added sodium borohydride (6.6 kg, 175 moles) and tetrahydrofuran (157 L). After cooling to -5+5C, trifluoroacetic acid (24.8 kg, 218 moles) was added while maintaining the temperature below 15 C. The solution was stirred 30 min at 1 5+5C and was then added to the reaction mixture resulting from step (i), keeping the temperature at less than 20C. This was stirred at 20+5C until reaction was complete. The solution was then cooled to 10+5C and quenched with 3N NaOH (195 kg). After agitating with tert-butyl methyl ether (162 L), the organic layer was separated and washed one time with 0.5N NaOH (200 kg), one time with 20% w/v aqueous ammonium chloride (195 kg), and two times with 25% aqueous sodium chloride (160 kg). The organics were stripped to give the desired product as an oil whichwas used directly in the next step.
IR (CHCI3) 3510, 3400, 3110, 3060, 3030,1630, 1H NMR (300 MHz, CDCI3) â 7.2 (m, 20H), 4.1 (d, 2H, J = 13.5 Hz), 3.65 (m, 1 H), 3.5 (d, 2H, J = 13.5 Hz), 3.1 (m, 2H), 2.8 (m, 1 H), 2.65 (m, 3H), 1.55 (m, 1 H), 1.30 (m, 1 H), 1 3C NMR
(300 MHz, CDCI3) ~140.8, 140.1, 138.2, 129.4, 129.4, 128.6, 128.4, 128.3, 128.2, 126.8, 126.3, 125.7, 72.0, 63.6, 54.9, 53.3, 46.2, 40.1, 30.2.

r~

Example 2F
(2S. 3S. 5S)-2.5-Diamino-3-hydroxy-1.6-diphenylhexane Dihydrochloride To a stirred solution of [2S,3S ,5S]-2-(N,N-dibenzylamino)-3-hydroxy-5-amino-1,6-diphenylhexane (20 kg, 43.1 mol) in methanol (250 kg) was added an aqueous solution of ammonium formate (13.6 kg, 215 mol) in water (23 kg) and an aqueous suspension of 5% wet palladium on carbon (4.0 kg, Degussa catalyst, E101 NE/W, approximately 50-60 % water by weight). The suspension which resulted was heated to reflux (70 + 10 C) for 6 hours and then cooled to room temperature. The suspension was filtered through a bed of diatomaceous earth and the cake was washed with methanol (2 X 30 kg). The filtrate was concentrated via vacuum distillation to an aqueous oil. The aqueous residue was taken up in 1 N NaOH (200 liters) and extracted with ethyl acetate (155 kg).The organic product layer was washed with a 20% aqueous sodium chloride solution (194 kg) and then with water (97 kg). The ethyl acetate product solution was then concentrated to an oil under vacuum distillation. Isopropanol (40 kg) was then charged to the residue and again the solution was concentrated to an oil with vacuum distillation. To the oil was charged isopropanol (160 kg) and concentrated aqueous hydrochloric acid (20.0 kg). The suspension / solution was then heated to reflux for 1 hour and then slowly cooled to room temperature. The slurry was then stirred for 12-16 hours. The slurry was filtered and the cake was washed with ethyl acetate (30 kg). The wet cake was resuspended in isopropanol (93 kg) and water (6.25 kg) and heated to reflux for 1 hour with stirring. The reaction mixture was then slowly cooled to room temperature and stirred for 12-16 hours. The reaction mixture was filtered and the wet cake was washed with isopropanol (12 kg). The solid was dried in a vacuum oven at 45 C for approximately 24 hours to provide 7.5 kg of the desired product.1H NMR (300 MHz, CD30D) ~7.40-7.15 (m,10H), 3.8 (ddd,1H, J = 11.4, 3.7, 3.7 Hz), 3.68-3.58 (m,1 H), 3.37 (ddd,1 H, J=7.5, 7.5,3.5 Hz), 3.05-2.80 (m, 4H),1.95-1.70 (m,2H),13C NMR (300MHz, CD30D) ~135.3,135.1, 129.0, 128.9,128.7,128.7,127.12,127.07, 67.4, 57.1, 51.6, 38.4, 35.5,35.2.

ExamPle 3 (2S,3S,5S)-2-Amino-3-hYdroxY-5-(t-butYloxycarbonyl-5amino)-1,6-diPhenylhexane Example 3A
(2S,3S,5S)-2-(N,N-dibenzYlamino)-3-hydroxy-5-(t-butYloxYcarbonYlamino)-1,6-diphenylhexane 10To a stirred solution of (2S,3S,5S)-2-(N,N-dibenzylamino)-3-hydroxy-5-amino-1,6-diphenylhexane (10.0 g, 21.6 mmol) in tetrahydrofuran (200 mL) was added potassium carbonate (6.0 g, 43.2 mmol) in HzO
(200 mL). To this solution was added di-t-butyldi-15carbonate (5.64 g. 25.9 mmol) in tetrahydrofuran (10 mL). The solution which resulted was stirred at room temperature for 3 hours. N,N-dimethylethylenediamine (1 mL, 8.6 mmol) was added and the reaction mixture was stirred at room temperature for an additional hour. Ethyl acetate (400 mL) was added and the organic layer was separated and washed with 5% KH2PO4 (2 x 200 mL), water (1 x 200 mL), saturated NaHCO3 (2 x 200 mL) and water (1 x 200 mL). The organic solution was then dried over sodium sulfate and concentrated under reduced pressure to provide the desired product as a light yellow oil. 300 MHz lH NMR
(CDC13) ~ 1.40 (s, 9H), 1.58 (s, 2H), 2.45-2,85 (m, 4H), 3.05 (m, lH), 3.38 (d, 2H), 3.6 (m, lH), 3.79 (m, lH), 3.87 (d, 2H), 4.35 (s, lH), 4.85 (s, broad, lH), 7.0-7.38 (m, 20H).

~i -32a- 21 35890 ExamPle 3B
(2S,3S,5S)-2-amino-3-hYdroxY-5-(t-butYloxy-5carbonYlamino)-1,6-diPhenYlhexane To a stirred solution of (2S,3S,5S)-2-(N,N-dibenzylamino)-3-hydroxy-5-(t-butyloxycarbonylamino)-1,6-diphenylhexane (12 g, 21.3 mmol) in methanol (350 mL) was charged ammonium formate (8.05 g, 128 mmol, 106.0 eq) and 10% palladium on carbon (2.4 g). The solution was stirred under nitrogen at 60C for three hours and then at 75C for 12 hours. An additional amount of ammonium formate (6 g) and 10% palladium on carbon (1.5 g) was added as well as 1 mL of glacial acetic acid. The reaction was driven to completion within 2 hours at a reflux temperature. The reaction mixture was then cooled to room temperature and then filtered through a bed of Celite (Trade Mark). The filter cake was I washed with methanol (75 mL) and the combined filtrates were concentrated under reduced pressure. The residue was taken up in 1 N NaOH (300 mL) and extracted into methylene chloride (2 X 200 mL). The combined organic layers were washed with brine (250 mL) and dried over sodium sulfate.
Concentration of the solution under reduced pressure provided the desired product as a light colored oil which slowly crystallized upon standing (5 g).
Further purification of the product could be accomplished by flash chromatography (silica gel, 5% methanol in methylene chloride). 300 MHz 1 H
NMR (CDCI3) ~ 1.42 (s,9H),1.58 (m,1 H),1.70 (m,1 H), 2.20 (s, broad, 2H), 2.52 (m,1 H), 2.76-2.95 (m,4H), 3.50 (m,1 H), 3.95 (m,1 H), 4.80 (d, broad,1 H),7.15-7.30 (m,10H).

Example 4 Alternative Preparation of (2S.3S.5S)-2-Amino-3-hydroxy-5-(t-butyloxycarbonylamino)-1.6-diphenylhexane .

Example 4A
(5S)-2-(t-Butyloxycarbonylamino)-5-(N .N-dibenzylamino)-1.6-diphenyl-4-oxo-2-hexene To 9.21 gm (20 mmol) of the resultant compound of Example 2D and 0.37 gm (3 mmol) 4-N,N-dimethylaminopyridine in 100 ml of methyl tert-butylether was added via syringe pump a solution containing 4.80 gm (22 mmol) di-tert-butyl dicarbonate in the same solvent (25 ml) over a period of 6 h. An additional amount (3 ml) of methyl tert-butylether was then added to complete the addition.After stirring at room temperature for 18 h the reaction mixture was cooled withthe aid of an ice water bath. The resultant solid was collected by suction filtration and washed with cold (0C) methyl tert-butylether and hexane and dried under vacuum to give 9.9 gm of crude material as a white solid. The material thus isolated was disolved in a minimal amount of dichloromethane and purified by flash chromatography on silica gel. Elution of the column with a mixture of hexane-ethyl acetate-dichloromethane (8:1 :1) gave, after concentration of the appropriate fractions, 8.1 gm (72%) of the desired compound. Mp. 191 - 193C.
[Ol]D -183.7 (c = 1.05, CHCI3).1 H NMR (CDCI3, ~): 11.68 (bs,1 H), 7.05 - 7.47 ~;;'' I (m, 20H), 5.28 (s,1 H), 4.27 (d, J=16 Hz,1 H), 4.02 (d, J=16Hz,1 H),3.58 (m, 4H), 3.40 (m,1 H),3.11 (m,1 H), 2.90 (m,1 H),1.48 (s,9H).

Example 4B
Alternate preparation of (5S)-2-(t-Butyloxycarbonylamino)-5-(N.N-dibenzylamino)-1.6-diphenyl-4-oxo-2-hexene A suspension of (S)-2-amino-5-(N,N-dibenzylamino)-1,6-diphenyl-4-oxo-2-hexene (100.0 g, 0.217 mol) in 15% ethyl acetate/hexanes (2 liters) under N2 was warmed to about 40C. The resulting solution was cooled to room temperature before adding 4.0 g (33 mmol) of N,N-dimethyl-4-aminopyridine and 49.7 g (0.228 mol) of di-tert-butyl dicarbonate. The reaction mixture was allowed to stir overnight at room temperature. (After approximately one hour, a white precipitate began to form.) The suspension was filtered and the precipitate was washed with hexanes to afford the desired product as colorless crystals. TLC: 25% ethyl acetate/hexanes Rf 0.38.

Example 4C
(2S. 3S. 5S)-2-(N.N-Dibenzylamino)-5-(t-butyloxycarbonylamino)-3-hydroxy-1.6-diphenylhexane.
A solution of the product of Example 4A (5 g, 8.9mmol) in dichloromethane (100ml) and 1,4-dioxolane (100ml) was cooled to between -10 and -15 C and treated dropwise with 1M BH3THF (26.7ml, 26.7mmol).
The solution was stirred at this temperature for 3 hr. The clear solution was quenched with excess methanol (20ml) and stirred at room temperature for 30 min. The solvent was removed in vacuo.
The resulting white foam was dissolved in THF (75ml) and cooled to -40 C. A solution of LAH (9ml,1M in THF, 9mmol) was added dropwise. After 10 min. the solution was quenched with water followed by dilute aqueous HCI.
The organics were removed and the aqueous layer extracted with ethyl acetate (3 x 20 ml). The combined organics were washed (saturated aqueous ~r bicarbonate followed by brine), dried (Na2so4)~ filtered and evaporated to afford 4.9 9 (99%) of the desired product as a white foam.
Alternatively, the white foam resulting from the BH3THF reaction step was dissolved in MeOH (45ml), cooled to +3 C and tre,ated portionwise with KBH4 (1.44 g, 26.7 mmol). After addition of the last portion of KBH4 the reaction wasstirred for an additional 4 hours at +4 to +5 C. The solution was concentrated by 1/2 the volume in vacuo, diluted with 1/1 hexane-EtOAc (70 ml) and quenched (with cooling, maintain temp. c30 C) by adding a 10 % solution of KHSO4 to pH = about 5. NaOH (15 % aqueous) was added to pH = 12 - 13.
The insoluble salts were removed by filtration, and the filter cake washed 3 times with 7 ml 1/1 hexane/EtOAc. The filtrate and washes were transferred to a separatory funnel, diluted with 15 ml hexane and 15 ml H2O. The organics were removed and the aqueous layer was extracted once with 20 ml (1/1) hexane-EtOAc. The combined organics were washed (saturated brine), dried (Na2SO4), filtered, and evaporated to afford 5.2 g of the desired product which was used without further purification in subsequent reactions.
Rf 0.5 (25% EtOAc/hexane) 1 H NMR (CDCI3) ~ 7.37-7.10 (m 20H); 6.78 (br. s, 1H); 4.62 (d,1H); 4.50 (s, 1H); 4.18 (dd,1H); 3.9 (d, 2H); 3.65 (dd, 2H); 3.40 (d, 2H); 3.00 (m, 2H); 2.77 (m,1H); 1.39 (s,9H). MS (El) m/e565 (M+H).

Example 4D
(2S. 3S. 5S)-2-Amino-3-hydroxy-5-(t-butyloxycarbonylamino)-1.6-diphenylhexane.
A solution of the product from Example 4C (150 gm, 250 mmol) dissolved in absolute EtOH (2 liters) was treated with 10 % Pd/C (18gm, pre-wetted), followed by addition of ammonium formate (78.6 gms, 1.25 moles) dissolved in H2O (200ml). The resulting mixture was stirred at reflux for 2.5 hours. The mixture was cooled to room temperature and filtered through a pad of infusorial earth (20g). The filter cake was washed 3 times with EtOH (70ml each). The filtrate was concentrated in vacuo. The residue was dissolved into EtOAc (1 L) and washed (1 N NaOH, followed by H2O, followed by brine), dried (Na2SO4), filtered and concentrated in vacuo. to a constant weight of 95 gms. (99.2 % of 2l 3~sa theory). The light yellow solid (91.5 gm of the 95 gm) was slurried in hot heptane (600 ml) (steam bath) and treated with isopropanol (45ml), and swirled to effect solution. The solution was allowed to slowly cool to room temperature over 3 hours, ~ept at room temperature for 2 more hours and filtered. The filtercake was washed 10 times with 9/1 hexane-isopropanol (30ml each) to give the desired product as an off-white finely crystalline solid which was dried to constant weight of 57.5 gm.
The crude product (20 gm) was recrystallized from hot 140 ml heptane/
17 ml isopropanol. After letting the solution cool slowly to room temperature, the mixture was let stand at room temperature for 2 hours and then filtered. The filter cake was rinsed (5 X 15 ml (8/1) heptane/isopropanol) and dried to a constant weight of 18.5 gm.

Example 5 Alternative Preparation of (2S.3S.5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane Example 5A
(2S.3S.5S)-5-(t-Butyloxycarbonylamino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane The product of Example 4D (6.09,15.6 mmoles) was dissolved in 60 mL
of DMF under nitrogen atmosphere. To this stirred solution at room temperature was added 5-(p-nitrophenyloxycarbonyloxymethyl)thiazole (4.679, 15.6 mmole) and the resulting solution was stirred for 4 h. The solvent was removed under reduced pressure by rotary evaporation and the residue dissolved in 150 mL
EtOAc. This solution was washed with 5 x 75 mL 1 N NaOH solution, 100 mL
brine, dried over Na2SO4. The solvent was removed to afford 8.02 g of a slightly yellowish oil. This material was crystallized from 30 mL EtOAc and 40 mL hexane to afford 6.539 (80%) of the desired product as a white solid. mp 118-120 C H 1NMR (CDCI3) ~ 8.79 (s, 1H), 7.83 (s, 1H), 7.30-7.15 (m, 8H), 7.08 (m, 2H),5.23 (s,2H),5.14 (d,1 H, J = 9 Hz), 4.52 (m,1 H),3.92-3.72 (m, 3H),3.65 (m,1 H), 2.85 (d-apparent, 2H, J = 7.5 Hz), 2.72 (d-apparent, 2H, J = 7 Hz), 1.61 (m, 2H),1.38 (s,9H). CIMS m/z (526) (M + H)+,543 (M + 18)+.

~''` .

Example 5B
(2S.3S.5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane The product of Example 5A (6.439, 12.23 mmoles) was dissolved in 25 mL dioxane at room temperature under nitrogen atmosphere. To this stirred solution was added 20.25 mL of 4N HCI in dioxane, and after approximately 10 min a thick precipitate formed. An additional 10 mL of dioxane was added to loosen up the slurry. This mixture was stirred for 1 h and then filtered. The filter cake of the product bis-HCI salt was washed with 20 mL dioxane, air dried, and then dissolved in 175 mL water. To this solution was added 175 mL ethyl acetate and the two phase mixture rapidly stirred. The pH of this mixture was adjusted to pH = 10 by the dropwise addition of 3N NaOH to the rapidly stirred mixture. The organic layer was isolated, washed with brine (150 mL), and dried over Na2SO4. The solvent was removed to afford 5.189 (99%) of the desired product as a clear oil. H1 NMR (CDCI3) ~ 8.81 (s, 1 H), 7.87 (s, 1 H), 7.35-7.05(m,10 H), 5.33 (d,1 H, J = 9.3 Hz), 5.28 (m,2H), 3.81 (m,1 H), 3.72 (m,1 H),3.01(m, 1H), 2.88 (m, 2H), 2.78 (dd,1H, J = 13.5, 5.1 Hz), 2.39 (dd, 1H, J = 9.0, 4.5 Hz),1.57-1.30 (m, 2H). CIMS m/z 426 (M + H)+.

Example 5C
(2S.3S.5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine (4.13g, 13.18 mmole) and hydroxybenztriazole (2.239, 16.48 mmoles) were dissolved in 70 mL THF and then dicyclohexyl-carbodiimide( 2.719, 13.18 mmoles) was added in one portion to the stirred solution under nitrogen atmosphere. This mixture was stirred for 4h at room temperature and then filtered to remove dicyclohexylurea precipitate. The product of Example 5B
(5.19, 11.99 mmoles) was dissolved in 100 mL THF under nitrogen atmosphere. To this stirred solution was added the filtrate of HOBT-active esterand the resulting solution was stirred at room temperature for 4 h, and the solvent removed via rotary evaporation. The residue was dissolved in 150 mL

ethyl acetate and washed with 2 x 100 mL 1N NaOH, 100 mL brine, 100 mL of 1 1% w/w aqueous KHSO4 and the solvent was removed by rotary evaporation to afford a residue. The residue was dissolved in 175 mL 1N HCL, and the solution filtered to remove the small quantity of dicyclohexylurea. The filtratesolution was added to 175 mL ethyl acetate and the two phase mixture rapidly mixed. The pH of this rapidly stirred mixture was adjusted to pH = 7 by dropwiseaddition of cold 3N NaOH. The organic layer was isolated, washed with 100 mL
brine, dried over Na2SO4, filtered, and the solvent was removed to afford 8.6 g of a colorless foam. This material was crystallized from 42 mL EtOAc and 21 mL
hexane to give 7.85g of the desired product as a white solid. mp = 122-123 C.
CIMS m/z 721 (M + H) +.

Example 6 Alternative Preparation of (2S.3S.5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane Alternative A
The product of Example 2F (9.5 g, 33.4 mmol) and phenylboronic acid (4.1 9, 33.6 mmol) were combined in toluene (150 mL) and refluxed for 2.5 hours with azeotropic water removal (Dean-Stark trap). Toluene (100 mL) was distilled out at atmospheric pressure, then the remaining toluene was removed under vacuum, to provide a yellow syrup which was dissolved in DMF (50 mL) and cooled to -60 C. A solution of 5-(p-nitrophenyloxycarbonyloxy-methyl)thiazole (9.5 9, 33.5 mmol) in DMF (50 mL) was added over 45 minutes.
The resulting mixture was stirred for 8 hours at -55+5 C, then 14 hours at -25C, then was allowed to warm to room temperature. The reaction mixture was diluted with 1 N HCI (250 mL) and washed with CH2CI2 (2 x 80 mL). The combined organic layers were back-extracted with 1 N HCI (60 mL). The combined aqueous HCI layers were cooled in an ice~bath to 2 C, and conc.
(37%) HCL (30 mL) was added over 5 minutes. The desired product (bis HCI
salt) began to precipitate within 30 minùtes. The slurry was stirred 3 hours at 2-5 C, then the product (bis HCI salt) was collected by filtration and dried in avacuum oven at 55-60 C. Yield 11.4 9 (68%).

~' i Second crop recovery:
The HCI mother liquors were stirred with ethyl acetate (190 mL) and neutralized to pH 9-10 with aqueous K2CO3 (200-300 g of 25% w/w K2CO3 was required). The ethyl acetate layer was concentrated under vacuum to an oil which was redissolved in 1 N HCI (90 mL) and washed with methylene chloride (45 mL). The aqueous layer was cooled to 2 C. Conc. (37%) HCI (9.0 mL) was added to precipitate a second crop. After stirring for 1-3 hours at 2-5 C, the solid was collected by filtration and dried in a vacuum oven at 55-60 C. Yield 2.1 g (12.6%).

Neutralization of Bis HCI Salt:
The bis HCI salt (10.66 g, 21.4 mmol, mixture of first and second crops) was stirred with CH2CI2 (110 mL) and 5% aqueous NaHCO3 (110 mL) until all solids dissolved (2 hours). The aqueous layer was separated and extracted with another 50 mL CH2CI2. The combined organic extracts were dried with Na2SO4 (10 g), filtered and concentrated under vacuum at <40 C to an oil. The oil was dried on a vacuum pump to give the title compound as a yellow foam, 9.1 g (100 %).

Alternative B
The product of Example 2F (15.0 g, 0.053 mole) was dissolved in DMF
(75 mL). Triisopropylborate (24.4 mL, 0.105 mole) was added and stirred at ambient temperature for approximately 1.5 hours. The solution was cooled to -10C and a solution of 5-(p-nitorphenyloxycarbonyloxymethyl)thiazole (15.0 g, 0.054 mole) in DMF (75 mL) was added over 80 minutes. The reaction was stirred for approximately 1 hour at -10 C, then was diluted with methylene chloride (250 mL) and quenched with a mixture of triethanolamine (24.8 g) and 5% aqueous sodium bicarbonate (300 mL). The biphasic mixture was stirred for 1 hour, then the layers were separated and the aqueous was extracted with another portion of methylene chloride (50 mL). The combined organic layers were extracted with 1 N HCI (1 x 390 mL, then 1 x 95 mL). The acid layers were combined, cooled in an ice-bath, and further acidified with conc. HCI (50 mL) which produced a white slurry of product. The slurry was stirred for 2135sgO

approximately 1 hour at 2C. The desired product bis HCI salt) was collected by filtration and dried at 55 C in a vacuum oven. Yield 18.5 g (70%).

Exam~le 7 Alternative Preparation of (2S.3S.5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl~methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1.6-diphenyl-3-hydroxyhexane To a solution of the product of Example 6 (9.1 g, 21.4 mmol), HOBT (3.6 9, 23.5 mmol) and N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)-L-valine (7.37 9, 23.5 mmol) in THF (170 mL) was added DCC (4.85 9, 23.5 mmol). The solution was stirred at ambient temperature for 16 hours (DCU precipitates). THF was removed under vacuum and the resulting paste was stirred with cold 1 N HCI (106 mL at 5 C) for 3 hours to dissolve the the crude product. The DCU was removed by filtration and the filter cake was washed with 1 N HCI (30 mL). KH2PO4 (3.2 9) was dissolved in the combined HCI filtrates. The solution was mixed with ethyl acetate (80 mL) and neutralizedto pH 7 with aqueous NaOH (60.3 9 of 10% w/w NaOH). The aqueous layer was extracted with another 25 mL ethyl acetate and the combined ethyl acetate extracts were washed with aqueous NaHCO3 (2 x 37 mL of 5% w/w NaHCO3).
The organic layer was dried with Na2SO4 (13 g), filtered, and concentrated under vacuum at <45 C. The residue was dissolved in a 1 :1 ethyl acetate/heptane mixture (200 mL) at 70 C. The solution was allowed to cool slowly and stirred overnight at room temperature to provide a thick slurry. The product was collected by filtration and washed with ~:1 ethyl acetate/heptane (20 mL). The product was dried briefly at 55 C in a vacuum oven to obtain an approximate weight prior to the second crystallization (12.85 9, 83%).

A second crystallization from 144 mL of 2:1 ethyl acetate/heptane (dissolved at ~70 C, then stirred at room temperature 12 hours) produced a thick slurry of fine white solid. The product was collected by filtration and washed with 15 mL
2:1 ethyl acetate/heptane, then dried in a vacuum oven at 55 C for 2 days to give the desired product. Yield 11.9 9 (77%).

~".

-41- ~135890 Exam~le 8 Alternate Preparation of ((5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate Exam~le 8A
2-Amino-5-(ethoxycarbonyl)thiazole Hydrochloride To a -10 C solution of potassium tert-butoxide (110 9, 0.98 mol) in THF
(1.9 L) was added a solution of ethyl chloroacetate (100 mL, 0.934 mol) and ethyl formate (75 mL, 0.928 mol) in THF (400 mL) dropwise over 2 hours, with good mechanical stirring. The thick solution was stirred another 2 hours at ca.
-1 C then the reaction was quenched by addition of a solution of NaCI (150 9) in 1 N HCL (750 mL). The mixture was allowed to warm to 20 C and the lower aqueous layer (containing some precipitated salt) was separated. The organic layer was stripped under vacuum on a rotary evaporator. The oil was redissolved in 500 mL ethyl acetate, dried with 75 g Na2SO4 for 1 hour, filteredand concentrated under vacuum (40-50 C bath temperature) to an oil. The resulting crude chloroaldehyde (161 g) and thiourea (70 g, 0.92 mol) were dissolved in THF (2 L) and warmed to gentle reflux (60 C). The thiourea dissolved during warming, and within 20 minutes, product precipitated from solution. After 100 minutes the suspension was allowed to cool to room temperature, then was cooled in an ice-bath for 1 hour. The product was collected on a fritted Buchner funnel and washed with 2 x 100 mL cold THF, then dried overnight in a vacuum oven at 50 C. Yield: 122 9 of title compound as a tan-colored solid, m.p. 182-185 C (dec.). 1 H NMR (DMSO-d6) ~ 7.86 (s, 1 H), 4.19 (q, 2H),1.21 (t, 3H). 13C NMR (DMSO-d6) ~ 171.9,160.4,140.4, 114.4, 61.1,14.2.
Example 8B
2-Amino-5-(ethoxycarbonyl)thiazole To a -10 C solution of potassium tert-butoxide (150 9,1.3 mol) in THF
(1.35 L) was added a solution of ethyl chloroacetate (139 mL,1.3 mol) and ethyl formate (103 mL,1.27 mol) in THF (150 mL) dropwise over 75 minutes, with good mechanical stirring. A THF rinse (25 mL) was added over 5 minutes. The thick solution was stirred anothet 3 hours at ca. -5 to 0 C, then the reaction was quenched by addition of a solution of NaCI (240 g) and conc. HCI (90 mL) in , ~
,.~

water (960 mL). The mixture was allowed to warm to 15 C and the lower aqueous layer was discarded. Thiourea (97 g, 1.27 mol) was dissolved in the crude THF solution of chloroaldehyde. The solution was warmed to 65 C and refluxed for 1 hour, then cooled to 30 C. Addition of a solution of K2CO3 (88g,0.64 mol) in 1500 mL water produced two layers (aqueous pH-7). The THF
was removed under vacuum at <45 C, causing the product to precipitate as a yellow solid. The slurry was cooled to 15 C, and the product was collected on a fritted Buchner funnel and washed with 3 x 200 mL water, then dried 24 hours in a vacuum oven at 55 C to provide 151 g of title compound as a yellow solid, m.p.155-158 C. 1 H NMR (DMSO-d6) ~ 7.8 (br s, 2H, NH2), 7.62 (s,1 H), 4.13 (q, 2H),1.18 (t, 3H). 13C NMR (DMSO-d6) ~ 173.4, 161.3,147.9,114.5, 60.1, 14.3.

Exam~le 8C
5-(Ethoxycarbonyl)thiazole A solution of 2-amino-5-(ethoxycarbonyl)thiazole (50 g, 0.29 mmol) in a mixture of DMF (83 mL) and THF (317 mL) was added dropwise over 87 minutes to a stirred 41 C solution of isoamyl nitrite (59 mL; 0.44 mol) in DMF
(130 mL). A maximum temperature of 60 C was observed during the exothermic addition. After another 40 minutes the THF was removed under vacuum at 45 C. The concentrated DMF solution was cooled to 25 C and diluted with toluene (420 mL) and water (440 mL). The toluene layer was extracted with 3 x 120 mL water, then dried with Na2SO4 (50 9) for 1 hour. Afterfiltration the toluene layer was stripped on a rotary evaporater at 50 C bath temperature, then on a vacuum pump at 21 C. The crude residue containing the title compound weighed 65.6 g. This material was used directly in the next step. A sample of similarly prepared material was purified ~y column chromatog~aphy to give a yellow oil. 1H NMR (CDCI3) ~ 8.95 (s,1 H), 8.51 (s, 1H), 4.39 (q,2H),1.40 (t, 3H). 13C NMR (CDCI3) ~ 161.0,157.9,148.6,129.8, 61.6,14.1.

~,-.

Example 8D
5-(Hydroxymethyl)thiazole To a slurry of lithium aluminum hydride (9.0 g) in THF (633 mL) was added a solution of crude 5-(ethoxycarbonyl)thiazole (65.6 g from Example 8C) in THF (540 mL) over 95 minutes at 0-5 C. After an additional 25 minutes, the reaction was quenched at 5 C by sequential addition of water (8.1 mL),15%
NaOH (8.1 mL), and water (24.3 mL). After drying with Na2SO4 (44 g) for 2 hours, the slurry was filtered, and the filter cake was washed with 100 mL THF.
The combined filtrates were concentrated under vacuum at 45 C to a brown oil (39 g). The oil was fractionally distilled through a short-path apparatus. The product fractions distilled at 97-104 C vapor temperature at 3-5 mm, providing 20.5 9 of the title compound as a turbid orange oil. 1 H NMR (CDCI3) ~ 8.74 (s, 1 H), 7.72 (s,1 H), 4.89 (s, 2H),3.4 (br s,1 H, OH). 13C NMR (CDCI3) ~ 153.4, 140.0,139.5, 56.6.

Example 8E
5-(p-Nitrophenyoxycarbonyloxymethyl)thiazole Hydrochloride Distilled 5-(hydroxymethyl)thiazole (14.1 g, 123 mmol) and triethylamine (17.9 mL, 129 mmol) were dissolved in ethyl acetate (141 mL) and cooled to -1 C (ice/salt bath). A solution of 4-nitrophenyl chloroformate (26.0 g,129 mmol) dissolved in ethyl acetate (106 mL) was added dropwise over 50 minutes at an internal temperature of 0-4 C. An ethyl acetate flask rinse (20 mL) was also added. Salts precipitated from solution throùghout the addition. The yellow mixture was stirred another 1 hour 45 minutes at 0-2 C, then a solution of dilute HCI (3.1 9,31 mmol of conc. HCI in 103 mL water) was added at once.
The mixture was stirred for 0.5 hours while warming to 15 C, then stirring was stopped. The organic layer was washed twice with aqueous 5% K2CO3 solution (2 x 70 mL), then dried with Na2SO4 (30 g). After filtration the solution was concentrated under vacuum on a rotary evaporater (bath temperature of 41 C) to a brown oil (389). The crude 5-(p-nitrophenyoxycarbonyloxymethyl)-thiazole was dissolved in ethyl acetate (282 mL), then cooled in an ice bath to 2 C. Dry HCI gas (7.1 9, 195 mmol) was bubbled in slowly over 50 minutes (temperature 2-4 C). After stirring for another 1 hour 45 minutes at 2-4C, thesolid precipitate was collected on a sintered glass funnel under a nitrogen ,~

.~

li .
blanket and the flask was washed out with 50 mL cold ethyl acetate whlch was used to rinse the filter cake. The cake was dried on the funnel under strong - nitrogen purge for 15 minutes then dried in a vacuum oven at 50 C with a nitrogen purge to provide 29.05 g of the title compound as tan powder, m.p.
131 -135 C (dec.). 1 H NMR (DMSO-d6) ~ 9.21 (d,1 H), 8.27 (m, 2H), 8.06 (d, 1 H), 7.52 (m, 2H), 5.54 (s, 2H). 13C NMR (DMSO-d6) ~ 157.3,155.2,151.8, 145.3,143.7,131.9,125.5,122.7, 62.1.

Example 8F
5-(p-Nitrophenoxycarbonyloxymethyl)thiazole 5-(p-Nitrophenoxycarbonyloxymethyl)thiazole hydrochloride (3.0 g) was slurried in ethyl acetate (30 mL) and cooled to 10-15 C. A solutionof 5% aqueous potassium carbonate (30 mL) was added with rapid stirring.
After 15 minutes, stirring was stopped and the aque~us layer was separated.
The organic layer was dried with Na2SO4 (3 g), filtered, and solvent was distilled under vacuum to give 2.49 g of the title compound as a brown syrup which slowly solidified, m.p. 62-64 C. 1 H NMR (CDCI3) ~ 8.90 (d, 1 H), 8.29 (m, 2H), 8.01 (d,1H), 7.39 (m, 2H),5.52 (s, 2H). 13C NMR (CDCI3) ~ 155.4,155.2, 152.2,145.4,144.9,130.6,125.3,121.6, 61.9.

Exam~le 9 Alternative Preparation of N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine Exam~le 9A
Thioisobutyramide To a 1 liter three neck round bottom flask equipped with mechanical stirrer, nitrogen atmosphere, condensor, thermocouple and 15 C water bath was charged (26.0 g, 0.298 mols) isobutyramide followed by ( 19.9 9, 0.045 mols) phosphorous pentasulfide and 375 mls THF. This solution was stirred at 20 + 5 C for 3 hours, then was warmed to 60 C and stirred an additional 3 hours. The THF was removed under vacuum with a 50 C bath temperature to afford a yellow oil. This oil was neutralized with a solution of 5 9 NaOH,10 g NaCI and 90 9 water. Next the product was extracted into EtOAc (2 X 250 mls) and the combined organics reduced under vacuum to an oil. The oil was dissolved in 50 mls THF and again the solvent was removed under vacuum to give the desired product as a yellow oil. (yield approx. 27 grams, 88%).
Example 9B
2-lsopropyl-4-(((N-methyl)amino)methyl)thiazole The thioisobutyramide resulting from Example 9A was dissolved in 70 mls THF and added slowly to a solution of (34.1 9, .27 mols) 1,3-dichloracetone in 40 mls THF. A 10 ml rinse of THF was used to completely transfer the thioamide. The reaction wass carried out in a 250 m! flask with mechanical stirring under nitrogen atmosphere. The reaction temperature was maintained below 25 C during addition with a 15 + 5 C bath. The bath was kept in place for 1 hour after which it was removed and the reaction stirred for 18 hours. Next this stirred chloromethyl-thiazole solution was added to 376 mls (4.37 mols) 40 % aqueous methylamine solution at 15 C in a 1-liter flask. The temperature was maintained below 25 C during addition. After half an hour the bath was removed and the reaction stirred for 3 hours at ambient temperature. The solvent was removed under vacuum with a 50 C bath to an end volume of 310 mls. The residue was then basified with 50 g 10 % NaOH to pH 12 and extracted into methylene chloride (2 X 160 mls). The combined organics were then washed with 1 X 150 9 of 20 % ammonium chloride followed by 1 X 90 9 of 20 % ammonium chloride. The combined aqueous washes were then back extracted with 150 mls methylene chloride. The combined product methylene chloride layers were then extracted with 100 9 of a solution of 25 9 conc. HCI
and 75 9 water. This acidic product solution was then washed with 135 mls methylene chloride. Next the acidic product solution was cooled, then neutralized with 100 9 20 % NaOH solution. The product was extracted from this mixture with methylene chloride (2 X 135 mls). The solvent was removed under vacuum to afford the desired product as an amber oil. (yield approx. 28 grams) --46- 1 2 1 3~890 Example 9C
N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine Methyl Ester Into a 500 ml 3-neck round bottom flask equipped with mechanical stirrer, nitrogen atmosphere, thermocouple, heating mantle and condensor was charged the product of Example 9B (28.1 g, .165 mols), phenoxycarbonyl-(L)-valine (41.5 g, .165 mol) and 155 ml toluene. This solution was warmed to reflux (110 C) and stirred for three hours, then cooled to 20+ 5 C and washed with 2 X 69 ml 10 % citric acid followed by 1 X 69 ml water,1 X 116 mls 4 %
sodium hydroxide,1X 58 ml 4 % sodium hydroxide and finally 1X 58 ml water.
The organic product solution was then treated with 3 grams of activated carbon at reflux for 15 minutes, filtered through infusorial earth to remove carbon, and the carbon/infusorial earth cake was washed with 25 ml hot toluene. Next the solvent was removed to afford a brown oil which solidifed upon cooling. This brown solid was dissolved with warming in 31 ml EtOAc and 257 ml heptane at 60+5 C. This solution was slowly cooled to 25 C, stirred 12 hours, cooled further to 0C, and stirred 3 hours. The crystals were collected by filtration and washed with 50 ml 1 :9 EtOAc/Heptane. The solid was dried in a 50C vacuum oven for 12 hours to afford 41.5 grams of the desired product as a tan-colored solid (76.9%).

Example 9D
N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine To a one liter three neck flask was charged the product of Example 9C
(50 g, 0.153 mol), lithium hydroxide monohydrate (13 g, 0.310 mol), 200 ml THF
and 190 ml water. This hazy solution was stirred for 2 hours. The reaction was quenched with a solution of conc. HCI (32.4 g, 0.329 mol) in 65 mL water, the THF was removed under vacuum and the product extracted into methylene chloride (3 X 210 ml). (NOTE: If necessary, the pH of the aqueous layer should be adjusted to maintain pH 1-4 during the extractions.) The combined organics were then dried with 50 g sodium sulfate, filtered with a 150 ml methylene chloride rinse of the sodium sulfate, and the solvent was removed under vacuum. The product was dissolved in 450 ml THF and again the solvent was s ~,~

removed. Next the product was dissolved in 475 ml THF containing 0.12 9 butylated hydroxytoluene (BHT) for storage. If desired, the solvent can be removed under vacuum and the residual syrup dried in a vacuum oven at 55 C
to provide a glassy solid.

Fluoro~enic Assay for Screenin~ Inhibitors of HIV Protease The inhibitory potency of the compound of the invention can be determined by the following method.
A compound of the invention is dissolved in DMSO and a small aliquot further diluted with DMSO to 100 times the final concentration desired for testing. The reaction is carried out in a 6 X 50 mm tube in a total volume of 300 microliters. The final concentrations of the components in the reaction buffer are: 125 mM sodium acetate, 1 M sodium chloride, 5 mM dithiothreitol, 0.5 mg/ml bovine serum albumin, 1.3 ~lM fluorogenic substrate, 2% (v/v) dimethylsulfoxide, pH 4.5. After addition of inhibitor, the reaction mixture is placed in the fluorometer cell holder and incubated at 30C for several minutes.The reaction is initiated by the addition of a small aliquot of cold HIV protease.
The fluorescence intensity (excitation 340 nM, emmision 490 nM) is recorded as a function of time. The reaction rate is determined for the first six to eight minutes. The observed rate is directly proportional to the moles of substrate cleaved per unit time. The percent inhibition is 100 X (1 - (rate in presence ofinhibitor)/(rate in absence of inhibitor)).
Fluorogenic substrate: Dabcyl-Ser-Gln-Asn-Tyr-Pro-lle-Val-Gln-EDANS
wherein DABCYL = 4-(4-dimethylamino-phenyl)azobenzoic acid and EDANS =
5-((2-aminoethyl)amino)-naphthalene-1-sulfonic acid.
Table 1 shows the inhibitory potency of compound of the invention against HIV-1 protease.

Inhibitor Compound of Percent Concentration Example Inhibition (nanomolar) 79 0.5 f`f ~

1 2 1 3~890 I' Antiviral Activity The anti-HlV activity of the compound of the invention can be determined in MT4 cells according to the procedure of Kempf, et. al. (Antimicrob. Agents Chemother. 1991, 35, 2209). The ICso is the concentration of compound that gives 50% inhibition of the cytopathic effect of HIV. The LCso is the concentration of compound at which 50% of the cells remain viable.

Table 2 shows the inhibitory potency of compound of the invention against HIV 13B in MT4 cells.

Compound of IC50 LC50 Example (micromolar) (micromolar) 0.025-0.040 55 The compound of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limitedto the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such asdecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

~' -49- 2 ~
Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
Preferred salts of the compound of the invention include hydrochloride, methanesulfonate, sulfonate, phosphonate and isethionate.
The compound of the present invention can also be used in the form of esters. Examples of such esters include a hydroxyl-substituted compound of formula A which has been acylated with a blocked or unblocked amino acid residue, a phosphate function, a hemisuccinate residue, an acyl residue of the formula R*C(O)- or R~C(S)- wherein R~ is hydrogen, loweralkyl, haloalkyl, alkoxy, thioalkoxy, alkoxyalkyl, thioalkoxyalkyl or haloalkoxy, or an acyl residue of the formula Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)- wherein Rb and Rd are independently selected from hydrogen or loweralkyl and Ra is -N(Re)(Rf), ORe or -SRe wherein Re and Rf are independently selected from hydrogen, loweralkyl and haloalkyl, or an amino-acyl residue of the formula R180NH(CH2)2NHCH2C(O)- or R1goNH(CH2)20CH2C(O)- wherein R180 is hydrogen, loweralkyl, arylalkyl, cycloalkylalkyl, alkanoyl, benzoyl or an a-amino acyl group. The amino acid esters of particular interest are glycine and Iysine;however, other amino acid residues can also be used, including those wherein the amino acyl group is -C(O)CH2NR20oR2o1 wherein R200 and R201 are independently selected from hydrogen and loweralkyl or the group -NR200R201 forms a nitrogen containing heterocyclic ring. These esters serve as pro-drugs of the compounds of the present invention and serve to increase the solubility of these substances in the gastrointestinal tract. These esters also serve to increase solubility for intravenous administration of the compounds. Other prodrugs include a hydroxyl-substituted compound of formula A wherein the hydroxyl group is functionalized with a substituent of the formula -CH(Rg)OC(O)R1g1 0r-cH(R9)oc(s)R1g1 wherein R1g1 is loweralkyl, haloalkyl, alkoxy, thioalkoxy or haloa!koxy and Rg is hydrogen, loweralkyl, haloalkyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl.
Such prodrugs can be prepared according to the procedure of Schreiber r~
~".

I' (Tetrahedron Lett. 1983, 24, 2363) by ozonolysis of the correspondingmethallyl ether in methanol followed by treatment with acetic anhydride.
The prodrugs of this invention are metabolized in vivo to provide the hydroxyl-substituted compound of formula A. The preparation of the prodrug esters is carried out by reacting a hydroxyl-substituted compound of formula A
with an activated amino acyl, phosphoryl, hemisuccinyl or acyl derivative as defined above. The resulting product is then deprotected to provide the desired pro-drug ester. Prodrugs of the invention can also be prepared by alkylation of the hydroxyl group with (haloalkyl)esters, transacetalzation with bis-(alkanoyl)acetals or condensation of the hydroxyl group with an activated aldehyde followed by acylation of the intermediate hemiacetal.
The compound of the invention is useful for inhibiting retroviral protease, in particular HIV protease, in vitro or in vivo (especially in mammals and in particular in humans). The compound of the present invention is also useful for the inhibition of retroviruses in vivo. especially human immunodeficiency virus (HIV). The compound of the present invention is also useful for the treatment orprophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection in a human or other mammal.
Total daily dose administered to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.001 to 300 mg/kg body weight daily and more usually 0.1 to 10 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
The compound of the present invention may be administered orally, parenterally, sublingually, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable ~r~

- - -I' carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
Injectable preparations, for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter andpolyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The compound of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically aceptable and metabolizable lipid capabale of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natureal and synthetic.
Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biolo~y. Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.
One preferred dosage form for the compound of the invention comprises a solid dosage form for oral administration comprising a pharmaceutically acceptable adsorbent to which is adsorbed a mixture of (1 ) a pharmaceutically acceptable organic solvent or a mixture of two or more pharmaceutically acceptable organic solvents, (2) a compound of the invention in the amount of from about 10% to about 40% by weight and (3) a total of from about 0.2 molar equivalents to about 2 molar equivalents (based on the compound of the invention) of a pharmaceutically acceptable acid. This composition is filled into hard gelatin capsules for administration. The preparation of a specific example of this type of dosage form is described below.

Solid-filled Capsule Dosa~e Form Preparation Propylene glycol (USP, 139 mL) and ethanol (dehydrated, USP, 200 proof, 139 mL) were mixed in a stainless steel or glass container. Hydrochloric acid (reagent grade, 20 mL) was added and mixed well. To this solution was added ascorbic acid (21 9) and the mixture was stirred until it was clear. The product of Example 1 U (200 9) was slowly added to the solution and mixing was continued until the solution was clear. Cremophore~' EL
(polyoxyethyleneglycerol oxystearate, 41 9) and polysorbate 80, NF (41 9) were added with mixing.

Microcrystalline cellulose, NF (139 9) and silicon dioxide, NF (Syloid 244, pharmaceutical grade, 209 9) were charged into a Hobart mixer and mixed for 3-5 minutes. The above solution was added dropwise to the dry mixture in the Hobart mixer ~hile mixing at slow speed. This mixture was massed until granular.
The wet granulation was screened through an 8 mesh screen. The screened granulation was spread on paper-lined trays and dried in a tray dryer or a fluidbed dryer (20-35C) until the loss on drying was not more than 12%.
The concentration of the product of Example 1-U (mg/g of granulation) in the granulation was determined by HPLC analysis. Capsules (gelatin, No. 00, iron gray opaque) were filled with the appropriate amount of the dried granulation to provide the desired dose per capsule.
While the compound of the invention can be administered as the sole active pharmaceutical agent, it can also be used in combination with one or more immunomodulators, antiviral agents, other antiinfective agents or vaccines. Other antiviral agents to be administered in combination with a compound of the present invention include AL-721, beta interferon, polymannoacetate, reverse transcriptase inhibitors ( for example, dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), BCH-189, 5-halo-3'-thia-dideoxycytidine, PMEA, zidovudine (AZT) and the like), non-nucleoside reverse transcriptase inhibitors (for example, R82193, L-697,661, Bl-RG-587 (nevirapine), retroviral protease inhibitors (for example, HIV protease inhibitors such as Ro 31-8959, SC-52151, KNI-227, KNI-272 and the like), HEPT
compounds, L,697,639, R82150, U-87201 E and the like), TAT inhibitors (for example, RO-24-7429 and the like), trisodium phosphonoformate, HPA-23, eflonithine, Peptide T, Reticulose (nucleophosphoprotein), ansamycin LM 427, trimetrexate, UA001, ribavirin, alpha interferon, oxetanocin, oxetanocin-G, cylobut-G, cyclobut-A, ara-M, BW882C87, foscarnet, BW256U87, BW348U87, L-693,989, BV ara-U, CMV triclonal antibodies, FIAC, HOE-602, HPMPC, MSL-109, Tl-23, trifluridine, vidarabine, famciclovir, penciclovir, acyclovir, ganciclovir, castanospermine, rCD4/CD4-lgG, CD4-PE40, butyl-DNJ, hypericin, oxamyristic acid, dextran sulfate and pentosan polysulfate. Immunomodulators that can be r 2 7 3~`9~
-54- ~
administered in combination with a compound of the present invention include bropirimine, Ampligen, anti-human alpha interferon antibody, colony stimulting factor, CL246,738, Imreg-1, Imreg-2, diethydithiocarbamate, interleukin-2, alpha-interferon, inosine pranobex, methionine enkephalin, muramyl-tripeptide, TP-5, erythropoietin, naltrexone, tumor necrosis facator, beta interferon, gammainterferon, interleukin-3, interleukin-4, autologous CD8+ infusion, alpha interferon immunoglobulin, IGF-1, anti-Leu-3A, autovaccination, biostimulation, extracorporeal photophoresis, FK-565, FK-506, G-CSF, GM-CSF, hyperthermia, isopinosine, IVIG, HIVIG, passive immunotherapy and polio vaccine hyperimmunization. Other antiinfective agents that can be administered in combination with a compound of the present invention include pentamidine isethionate. Any of a variety of HIV or AIDS vaccines (for example, gp120 (recombinant), Env 2-3 (gp120), HlVAC-1e (gp120), gp160 (recombinant), VaxSyn HIV-1 (gp160), Immuno-Ag (gp160), HGP-30, HlV-lmmunogen, p24 (recombinant), VaxSyn HIV-1 (p24) can be used in combination with a compound of the present invention.
Other agents that can be used in combination with the compound of this invention are ansamycin LM 427, apurinic acid, ABPP, Al-721, carrisyn, AS-101, avarol, azimexon, colchicine, compound Q, CS-85, N-acetyl cysteine, (2-oxothiazolidine-4-carboxylate), D-penicillamine, diphenylhydantoin, EL-10, erythropoieten, fusidic acid, glucan, HPA-23, human growth hormone, hydroxchloroquine, iscador, L-ofloxacin or other quinolone antibiotics, lentinan, lithium carbonate, MM-1, monolaurin, MTP-PE, naltrexone, neurotropin, ozone, PAI, panax ginseng, pentofylline, pentoxifylline, Peptide T, pine cone extract, polymannoacetate, reticulose, retrogen, ribavirin, ribozymes, RS-47, Sdc-28, silicotungstate, THA, thymic humoral factor, thymopentin, thymosin fraction 5, thymosin alpha one, thymostimulin, UA001, uridine, vitamin B12 and wobemugos.
Other agents that can be used in combination with the compound of this invention are antifungals such as amphotericin B, clotrimazole, flucytosine, fluconazole, itraconazole, ketoconazole and nystatin and the like.
Other agents that can be used in combination with the compound of this invention are antibacterials such as amikacin sulfate, azithromycin, C

, 2 1 35890 ciprofloxacin, tosufloxacin, clarithromycin, clofazimine, ethambutol, isoniazid,pyrazinamide, rifabutin, rifampin, streptomycin and TLC G-65 and the like.
Other agents that can be used in combination with the compound of this invention are anti-neoplastics such as alpha interferon, COMP
(cyclophosphamide, vincristine, methotrexate and p'rednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PRO-MACE/MOPP(prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, etoposide/mechlorethamine, vincristine, prednisone and procarbazine), vincristine, vinblastine, angioinhibins, pentosan polysulfate, platelet factor 4 and SP-PG and the like.
Other agents that can be used in combination with the compound of this invention are drugs for treating neurological disease such as peptide T, ritalin, lithium, elavil, phenytoin, carbamazipine, mexitetine,-heparin and cytosine arabinoside and the like.
Other agents that can be used in combination with the compound of this invention are anti-protozoals such as albendazole, azithromycin, clarithromycin,clindamycin, corticosteroids, dapsone, DIMP, eflornithine, 566C80, fansidar, furazolidone, L,671,329, letrazuril, metronidazole, paromycin, pefloxacin, pentamidine, piritrexim, primaquine, pyrimethamine, somatostatin, spiramycin, sulfadiazine, trimethoprim, TMP/SMX, trimetrexate and WR 6026 and the like.
Among the preferred agents for treatment of HIV or AIDS in combination with the compound of this invention are reverse transcriptase inhibitors.
It will be understood that agents which can be combined with the compound of the present invention for the treatment or prophylaxis of AIDS or an HIV infection are not limited to those listed above, but include in principle any agents useful for the treatment or prophylaxis of AIDS or an HIV infection.
When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

r ~
i ~~~.
~ .~ .

Claims (35)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. The compound of formula:

which is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopro-pyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-di-phenyl-3-hydroxyhexane; or a pharmaceutically accept-able salt or prodrug thereof, wherein the prodrug is selected from a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S) wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-, (vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein Rlgl is Cl -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl.

2. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopro-pyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-di-phenyl-3-hydroxyhexane.

3. A pharmaceutically acceptable salt of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane.

4. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopro-pyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-di-phenyl-3-hydroxyhexane; or a pharmaceutically accept-able salt or prodrug thereof, wherein the prodrug is selected from a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1-to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S) wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-(vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl for use in treating AIDS.

5. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopro-pyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-di-phenyl-3-hydroxyhexane, for use in treating AIDS.

6. A pharmaceutically acceptable salt of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopro-pyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-di-phenyl-3-hydroxyhexane, for use in treating AIDS.

7. A prodrug of claim 4, for use in treating AIDS.

8. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2 OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-(vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl in the manufacture of a medicament for inhibiting HIV
protease.

9. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-, (vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1-to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl, in the manufacture of a medicament for inhibiting HIV
infection.

10. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((Z-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, in the manufacture of a medicament for inhibiting HIV protease.

11. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, in the manufacture of a medicament for inhibiting HIV infection.

12. Use of a salt of claim 3, in the manufacture of a medicament for inhibiting HIV protease.

13. Use of a salt of claim 3, in the manufacture of a medicament for inhibiting HIV infection.

14. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-, (vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1-to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl, as an HIV protease inhibitor.

15. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, as an HIV protease inhibitor.

16. Use of a salt of claim 3, as an HIV protease inhibitor.

17. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-, (vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl, as an HIV infection inhibitor.

18. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; as an HIV infection inhibitor.

19. Use of a salt of claim 3, as an HIV
infection inhibitor.

20. An HIV protease inhibitor pharmaceutical composition comprising:
a therapeutically effective HIV protease inhibiting amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1-to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-(vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl, in association with a pharmaceutically acceptable carrier.

21. An HIV protease inhibitor pharmaceutical composition comprising a therapeutically effective HIV
protease inhibiting amount of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)amino)-1,6-diphenyl-3-hydroxyhexane; in association with a pharmaceutically acceptable carrier.

22. An HIV protease inhibitor pharmaceutical composition comprising a therapeutically effective HIV
protease inhibiting amount of a salt of claim 3, in association with a pharmaceutically acceptable carrier.

23. An HIV infection inhibitor pharmaceutical composition comprising:
a therapeutically effective HIV infection inhibiting amount of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)car-bonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycar-bonyl)amino)-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1-to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2 OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-(vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1-to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl, in association with a pharmaceutically acceptable carrier.

24. An HIV infection inhibitor pharmaceutical composition comprising a therapeutically effective HIV
infection inhibiting amount of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)car-bonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycar-bonyl)amino)-1,6-diphenyl-3-hydroxyhexane, in association with a pharmaceutically acceptable carrier.

25. An HIV infection inhibitor pharmaceutical composition comprising a therapeutically effective HIV

infection inhibiting amount of a salt of claim 3, in association with a pharmaceutically acceptable carrier.

26. A process for the preparation of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thia-zolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxy-hexane; or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6 alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1 -to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1 -to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S) wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-, (vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkylamino)carbonyl, comprising:
reacting (2S,3S,5S)-5-amino-2-(N-((5-thia-zolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxy-hexane with N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valine or an activated ester derivative thereof selected from the group consisting of an acid halide, an anhydride derived from formic acid, an anhydride derived from acetic acid, an anhydride derived from an alkoxycarbonyl halide, an ester derived from N-hydroxysuccinimide, an ester derived from N-hydroxyphthalimide, an ester derived from N-hydroxybenzotriazole, an ester derived from N-hydroxy-5-norbornene-2,3-dicarboxamide and an ester derived from 2,4,5-trichlorophenol, and when desired:
converting the (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, produced to a corresponding pharmaceutically accept-able salt or prodrug thereof.

27. Use of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino3-1,6-diphenyl-3-hydroxyhexane; or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is selected from:
a) esters wherein the acyl residue of the ester is (i) R*C(O)- or R*C(S)- wherein R* is hydrogen, C1 -to- C6-alkyl, halo - C1 -to- C6-alkyl, C1 -to- C6-alkoxy, benzyloxy, C1 -to- C6- thioalkoxy, benzylthio, C1 -to- C6- alkoxy- C1-to- C6 alkyl, benzyloxy -C1 to C6 alkyl, C1 -to- C6-thioalkoxy -C1 -to- C6-alkyl, benzylthio -C1 -to- C6-alkyl, halo - C1-to- C6-alkoxy or halobenzyloxy, (ii) Ra-C(Rb)(Rd)-C(O)- or Ra-C(Rb)(Rd)-C(S)-wherein Rb and Rd are independently selected from hydrogen or C1 -to- C6-alkyl and Ra is -N(Re)(Rf), -ORe or -SRe wherein Re and Rf are independently selected from hydrogen, C1 -to- C6-alkyl and halo -C1 -to- C6- alkyl, (iii) R180 NH(CH2)2NHCH2C(O)- or R180NH(CH2)2-OCH2C(O)- wherein R180 is hydrogen, C1 -to- C6-alkyl, benzyl, C3 -to- C7- cyclcoalkyl- C1-to-C6 alkyl, C1-to-C6-alkanoyl or benzoyl, (iv) C(O)CH2NR200R201 wherein the group NR200R201 forms a nitrogen-containing heterocycle selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thio-morpholinyl, (v) H2O3P-(vi) -C(O)CH2CH2COOH or (vii) -C(O)CH(NH2)((CH2)4NH2); or b) wherein the prodrug is a compound wherein a hydroxy group is functionalized with a substituent of the formula -CH(Rg)OC(O)R181 or -CH(Rg)OC(S)R181 wherein R181 is C1 -to- C6-alkyl, halo -C1 -to- C6-alkyl, C1 -to- C6- alkoxy, benzyloxy, C1 -to- C6-thioalkoxy, benzylthio-, halo -C1 -to- C6- alkoxy or halobenzyloxy and Rg is hydrogen, C1 -to- C6-alkyl, halo -C1 -to- C6- alkyl, C1 -to- C6- alkoxycarbonyl, benzyloxycarbonyl, aminocarbonyl, C1 -to- C6- alkyl-aminocarbonyl or di -(C1 -to- C6-alkyl)aminocarbonyl, in combination with one or more reverse transcriptase inhibitors for inhibiting HIV infection.

28. Use according to claim 27, wherein the one or more reverse transcriptase inhibitors are selected from zidovudine, dideoxyinosine, dideoxycytidine, BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, fluoro-thymidine, 5-halo-3'-thia-dideoxycytidine and PMEA.

29. Use according to claim 27, wherein the one or more reverse transcriptase inhibitors are selected from zidovudine, dideoxyinosine, dideoxycytidine, BCH-189, DDA, D4C, D4T and DP-AZT.

30. Use of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with one or more reverse transcriptase inhibitors for inhibiting HIV infection.

31. Use according to claim 30, wherein the one or more reverse transcriptase inhibitors are selected from zidovudine, dideoxyinosine, dideoxycytidine, BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, fluorothymidine, 5-halo-3'-thia-dideoxycytidine and PMEA.

32. Use according to claim 30, wherein the one or more reverse transcriptase inhibitors are selected from zidovudine, dideoxyinosine, dideoxycytidine, BCH-189, DDA, D4C, D4T and DP-AZT.

33. Use of a pharmaceutically acceptable salt of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)valinyl)amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, in combination with one or more reverse transcriptase inhibitors for inhibiting HIV infection.

34. Use according to claim 31, wherein the one or more reverse transcriptase inhibitors are selected from zidovudine, dideoxyinosine, dideoxycytidineBCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, fluorothymidine, 5-halo-3'-thia-dideoxycytidine and PMEA.

35. Use according to claim 33, wherein the one or more reverse transcriptase inhibitors are selected from zidovudine, dideoxyinosine, dideoxycytidine, BCH-189, DDA, D4C, D4T and DP-AZT.